Methods and cell structures
Patent Information
- Application Number
- JP2023530985
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-10-26
- Filing Date
- 2021-11-24
- Publication Date
- 2024-11-28
AI Technical Summary
Current methods lack the ability to create human blastocyst models in vitro due to challenges in inducing and maintaining human blastocyst stem cell types in culture, limiting our understanding of early human embryonic development and being constrained by ethical, legal, and policy issues.
A method involving reprogramming somatic cells to exhibit epiblast, trophectoderm, and primitive endoderm transcriptional signatures, followed by culturing under specific conditions to form multilayered cell structures that resemble blastocyst-like structures, using agents that activate WNT pathway signaling and culture media containing EGF and BMP4.
This approach allows for the creation of human blastocyst-like structures, known as iBlastoids, which mimic early human embryonic development and can be used for studying complex cellular and molecular interactions, providing a tractable model for research.
Smart Images

Figure 00000070_0000 
Figure 00000070_0001 
Figure 00000071_0000
Abstract
Description
[Technical Field]
[0001] The present invention relates to methods and compositions for generating human blastocyst-like structures.
[0002] Related Applications This application claims priority from Australian Provisional Patent Applications Australian Patent Application Publication Nos. 2020904338, 2021900685, 2021902865 and 2021903427, the contents of all of which are incorporated herein by reference in their entirety. [Background technology]
[0003] Mammalian embryonic development begins with a totipotent zygote, which has the capacity to develop into a morula and subsequently form a blastocyst. Following embryo implantation, cells of the epiblast (EPI) lineage within the blastocyst develop into the embryonic body and amnion, while cells of the trophectoderm (TE) and primitive endoderm (PE) ultimately give rise to the placenta and yolk sac, respectively.
[0004] Isolation and in vitro culture of epiblast cells gives rise to human embryonic stem cells (hESCs). Alternatively, mature cells can be reprogrammed into human induced pluripotent stem cells (hiPSCs) through transcription factor-mediated reprogramming. These pluripotent in vitro cultured cells can differentiate into any cell type of the body and have therefore been central to the development of human "mini-organ" or organoid models. Furthermore, hESCs / hiPSCs have been used to develop several in vitro models for studying early human development, including micropatterned scutellum-like structures, germ sac-like structures, and human gastruloids. This technological and medical revolution has been crucial for disease modeling, drug screening, and our understanding of the molecular mechanisms of several diseases, embryonic, and organ development.
[0005] However, despite the importance of the complex spatiotemporal, cellular, and molecular changes during the early phases of blastocyst development for the overall future of the individual, no integrated in vitro model of human blastocyst EPI / TE / PE has been reported. To date, the only way to study these crucial first days of human development is through the use of donor blastocysts that have consented to participate in research studies after in vitro fertilization (IVF). This poses numerous challenges, as the goal of IVF is almost always to generate embryos for reproductive purposes, leaving only surplus (potentially low-quality) embryos available for research use. This, combined with numerous ethical, legal, and policy constraints that vary worldwide, severely limits the number of laboratories permitted to work with human blastocysts and, therefore, our understanding of early human embryo development.
[0006] In the past few years, different groups have successfully generated in vitro mouse blastocyst models, called blastoids. These mouse blastoids have been generated using two different approaches: (1) by aggregating different blastocyst-like cells together, including mouse embryonic stem cells (ESCs) and trophoblast stem cells (TSCs); ESCs, TSCs, and extraembryonic endoderm (XEN) stem cells; expanded (or expanded) pluripotent stem cells (EPSCs) and TSCs; or (2) by differentiating EPSCs into blastocyst-like structures.
[0007] However, there have been no reports of the generation of human blastoids, likely due to the challenges of inducing stem cell types in human blastocysts and maintaining them in culture. Summary of the Invention [Problem to be solved by the invention]
[0008] Thus, there is a need to create human cellular constructs that model the human blastoid or human blastocyst. [Means for solving the problem]
[0009] The reference herein to any prior art is not an admission or suggestion that the prior art forms part of the common general knowledge within any legal jurisdiction or that the prior art could reasonably be expected to be understood, considered relevant, and / or incorporated into other pieces of prior art by those skilled in the art.
[0010] In one aspect, the present invention provides a method for making a multi-layered cell structure, comprising the steps of: a) obtaining a cell population of reprogrammed somatic cells that exhibit epiblast (EPI), trophectoderm (TE) and / or primitive endoderm (PE) transcriptional signatures; and b) culturing the reprogrammed somatic cells under conditions that allow aggregation to obtain multi-layered cell structures; thereby providing a method for producing a multi-layered cell structure.
[0011] In one aspect, the present invention provides a method of producing a blastocyst-like structure, comprising the steps of: a) obtaining a cell population of reprogrammed somatic cells that exhibit epiblast (EPI), trophectoderm (TE) and / or primitive endoderm (PE) transcriptional signatures; and b) culturing the reprogrammed somatic cells under conditions that allow aggregation to obtain blastocyst-like structures; thereby producing a blastocyst-like structure.
[0012] In any embodiment, obtaining a cell population of reprogrammed somatic cells exhibiting epiblast (EPI), trophectoderm (TE), and primitive endoderm (PE) transcriptional signatures comprises: - increasing the protein expression or amount of one or more factors in a population of somatic cells, the factors being for reprogramming the somatic cells toward a dedifferentiated or pluripotent state; and - culturing the cells for a time and under conditions sufficient to allow reprogramming of the cells towards a dedifferentiated or pluripotent state; Includes:
[0013] In any embodiment, the population of cells exhibiting transcriptional signatures of the epiblast (EPI), trophectoderm (TE) and / or primitive endoderm (PE) lineages preferably exhibits transcriptional signatures of each of the epiblast (EPI), trophectoderm (TE) and primitive endoderm (PE) lineages.
[0014] In any embodiment, a population of cells exhibiting a transcriptional signature of the EPI, TE, or PE lineage comprises a population of cells expressing at least one of the markers listed in Table 1 herein. More preferably, a transcriptional signature of the EPI lineage comprises expression of at least 2, at least 3, at least 4, at least 5, at least 10, at least 15, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, or more, or all, of the markers of the EPI lineage as listed in Table 1 herein. More preferably, a transcriptional signature of the TE lineage comprises expression of at least 2, at least 3, at least 4, at least 5, at least 10, at least 15, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, or more, or all, of the markers of the TE lineage as listed in Table 1 herein. More preferably, the transcriptional signature of the PE lineage comprises expression of at least 2, at least 3, at least 4, at least 5, at least 10, at least 15, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70 or more or all of the markers of the PE lineage as listed in Table 1 herein.
[0015] In one aspect, the present invention provides a method of producing a blastocyst-like structure, comprising the steps of: a) increasing the protein expression or amount of one or more factors in a population of somatic cells, the factors being for reprogramming the somatic cells towards a dedifferentiated or pluripotent state; b) culturing the cells for a time and under conditions sufficient to allow reprogramming of the cells towards a dedifferentiated pluripotent state to obtain a population of cells exhibiting one or more characteristics of the EPI, TE and PE lineages; c) contacting the cells with a culture medium comprising an agent that activates WNT pathway signaling (optionally a GSK-3 inhibitor), at least one, preferably two, TGF-β inhibitors, HDAC inhibitors, EGF, and BMP4 under conditions that allow aggregation; d) culturing the cells in a culture medium for a time and under conditions sufficient to allow the cells to exhibit at least one characteristic of a blastocyst-like structure as described herein. in order to produce a blastocyst-like structure.
[0016] Preferably, the culture medium in step c) further comprises a Rho kinase (ROCK) inhibitor. Preferably, the cells are contacted with the culture medium containing the ROCK inhibitor for a period of at least about 6 hours, at least about 12 hours, or at least about 24 hours before the cells are subsequently contacted with culture medium without the ROCK inhibitor.
[0017] It will be understood that any method of reprogramming somatic cells toward a dedifferentiated or pluripotent state can be used in accordance with the methods of the present invention. Thus, the present invention is not limited to a particular method of increasing protein expression or amount of relevant factors or culture conditions that allow somatic cells to initiate reprogramming toward plasticity or pluripotency. Such methods are known in the art and are further described herein.
[0018] In a preferred embodiment, the factors for reprogramming somatic cells toward a dedifferentiated or pluripotent state are transcription factors. The transcription factors can comprise, consist of, or consist essentially of one or more of the following factors: OCT4, SOX2, KLF4, and MYC (OSKM); SOX2, KLF4, and OCT4 (SKO); OCT4, SOX2, KLF4, and GLIS1 (OSKG); OCT4, SOX2, NANOG, and LIN28 (OSNL); or OCT4, SOX2, KLF4, c-MYC, NANOG, and LIN28 (OKSMNL). In a particularly preferred embodiment, the transcription factors comprise all four of the factors OCT4, SOX2, KLF4, and MYC (OSKM), or variants thereof. In another embodiment, the transcription factors comprise, consist of, or consist essentially of SOX2, KLF4, and OCT4 (SKO). In another embodiment, the transcription factors comprise, consist of, or consist essentially of OCT4, SOX2, KLF4, and GLIS1 (OSKG). In another embodiment, the transcription factors comprise, consist of, or consist essentially of OCT4, SOX2, NANOG, and LIN28 (OSNL). In another embodiment, the transcription factors comprise, consist of, or consist essentially of OCT4, SOX2, KLF4, c-MYC, NANOG, and LIN28 (OKSMNL).
[0019] Thus, in another aspect, the present invention provides a method of producing a blastocyst-like structure, comprising the steps of: a) increasing the protein expression or amount of one or more of the transcription factors OCT4, SOX2, KLF4 and MYC (OSKM), SOX2, KLF4 and OCT4 (SKO), OCT4, SOX2, KLF4 and GLIS1 or OCT4, SOX2, NANOG and LIN28 (OSNL) in a population of somatic cells, or any other combination of transcription factors described herein; b) culturing the cells for a time and under conditions sufficient to allow reprogramming of the cells towards a dedifferentiated, pluripotent state, preferably wherein the culture of the cells is in a medium suitable for the maintenance of somatic cells; c) contacting the cells with a culture medium comprising an agent that activates WNT pathway signaling (optionally a GSK-3 inhibitor), at least one, preferably two, TGF-β inhibitors, HDAC inhibitors, EGF, and BMP4 under conditions that allow aggregation; d) culturing the cells in a culture medium for a time and under conditions sufficient to allow the cells to exhibit at least one characteristic of a blastocyst-like structure as described herein. in order to produce a blastocyst-like structure.
[0020] Typically, the protein expression or amount of a transcription factor as described herein is increased by contacting a cell with an agent that increases the expression of the transcription factor. Preferably, the agent is selected from the group consisting of nucleotide sequences, proteins, aptamers and small molecules, ribosomes, RNAi agents, microRNAs, long non-coding RNAs, and peptide nucleic acids (PNAs), and analogs or variants thereof. In some embodiments, the agent is exogenous. The present invention also contemplates the use of a transcription activation system (e.g., gRNA for use in gene activation systems such as CRISPR / Cas9 or TALEN) to increase the expression of one or more transcription factors.
[0021] Typically, protein expression or amount of a transcription factor as described herein is increased by introducing into cells at least one nucleic acid (e.g., mRNA) comprising a nucleotide sequence encoding the transcription factor or encoding a functional fragment thereof. The at least one nucleic acid encoding the transcription factor can be transfected into a population of somatic cells multiple times, for example, 2, 3, 4, 5, or 6 times, for example, daily for 2, 3, 4, 5, or 6 days, respectively.
[0022] In a preferred embodiment of the present invention, the nucleic acid sequence encoding the transcription factor protein is introduced into the cell by a plasmid. One or more nucleic acids encoding one or more transcription factors may be used. It is therefore clear that one or more plasmids may be used to increase the expression or amount of one or more required transcription factors. In other words, the nucleic acid sequence may be in or on a single plasmid, or may be provided to the somatic cell on two or more plasmids.
[0023] In any embodiment of the invention, the plasmid containing nucleic acid encoding one or more transcription factors for use in accordance with the invention may be an episomal plasmid.
[0024] Preferably, the nucleic acid further comprises a heterologous promoter. Preferably, the nucleic acid is in a vector, such as a viral vector or a non-viral vector. Preferably, the vector is a viral vector that comprises a genome that does not integrate into the host cell genome. The viral vector may be a retroviral vector, a lentiviral vector, an adenovirus, or a Sendai virus.
[0025] In certain embodiments, the protein expression or amount of a factor is increased in somatic cells by transducing or transfecting the somatic cells with one or more vectors encoding the transcription factor. The vector may be a viral vector, including an integrative or non-integrative viral vector. In further embodiments, the vector may be an episomal vector.
[0026] It will also be understood that the somatic cells do not need to be completely reprogrammed to a pluripotent state before the step of contacting the cells with culture medium defined in step c). In other words, the cells are preferably in an intermediate state and are in transition from a differentiated state toward a more plastic or pluripotent state at the time of contacting the cells with culture medium. Thus, the cells at the end of step b) and before being cultured in step c) may be referred to as "reprogrammed intermediates." As described herein, the population of reprogrammed intermediates exhibits epiblast (EPI), trophectoderm (TE), and / or primitive endoderm (PE) transcriptional signatures. The population of reprogrammed intermediates produced according to the present invention may also be characterized by referring to the proportion of different cell populations that stain positively or negatively for the markers OCT4, GATA6, and CDX2, as shown in Figure 2h herein.
[0027] In certain embodiments, the period of culturing cells to initiate reprogramming toward a dedifferentiated or pluripotent state is at least one day, beginning after the increase in protein expression or amount of one or more factors or when the cells are contacted with an agent to increase protein expression or amount of one or more factors. This period can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 days or more after the increase in protein expression or amount of one or more factors. In any embodiment, the period of culturing cells to initiate reprogramming toward a dedifferentiated or pluripotent state can be any period of time that is capable of achieving a decrease in markers associated with somatic cells and / or causing a decrease or loss of somatic cell identity and the acquisition of cellular plasticity.
[0028] In one embodiment, the step of culturing the cells for a time and under conditions sufficient to allow reprogramming of the cells toward a dedifferentiated or pluripotent state comprises culturing the cells in a medium for maintaining somatic cells in culture. Preferably, this step comprises culturing the cells in a medium not intended to promote pluripotency. In other words, if the somatic cells to be reprogrammed are fibroblasts, preferably the cells are cultured in a medium suitable for maintaining fibroblasts. If the somatic cells to be reprogrammed are epithelial cells, preferably the cells are cultured in a medium suitable for maintaining epithelial cells. Media suitable for culturing and maintaining various somatic cell types are known to those skilled in the art and are further defined in Table 3b herein.
[0029] In another embodiment, culturing the cells for a time and under conditions sufficient to allow reprogramming of the cells toward a dedifferentiated or pluripotent state comprises culturing the cells in a medium not intended to promote pluripotency alone. Exemplary media include NACL, PA, or t2iLGo medium as defined herein, including those in Table 3a.
[0030] In a further embodiment of the invention, the method comprises culturing somatic cells toward a dedifferentiated or pluripotent state in a medium that induces upregulation of EPI, TE, and PE lineage transcriptional signatures. Preferably, when the somatic cells are fibroblasts, the medium is a fibroblast medium, e.g., a fibroblast medium as defined herein, including those in Table 3a or Table 3b.
[0031] In any embodiment, the period between increasing the protein expression or amount of the factor and contacting the cells with culture medium in step c) can be any period that allows for a decrease in markers associated with somatic cells. In a further example, the period between increasing the protein expression or amount of the factor and contacting the cells with culture medium in step c) can be any period that allows for the cells to progress through a mesenchymal-epithelial transition state. In further or alternative embodiments, this period can be any period that allows for the expression of epiblast (EPI), trophectoderm (TE), and primitive endoderm (PE) transcriptional signatures.
[0032] As used herein, the culture medium of step c) (i.e., the culture medium contacting the reprogrammed intermediates exhibiting EPI, TE, and PE lineage transcriptional signatures) may also be referred to as blastocyst-promoting medium or "iBlastoid" medium. Preferably, the blastocyst-promoting medium or iBlastoid medium is any as defined herein. In any embodiment, the cells in step c) are cultured in the culture medium for at least about 1, at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 9, at least about 12, at least about 14, at least about 16, at least about 20, at least about 24, or at least about 28 days or more.
[0033] In any embodiment, the conditions that allow for aggregation or self-organization may include culturing the cells in any culture plate, culture vessel, microfluidic device, or culture system that allows for three-dimensional aggregation or self-organization of the cells. For example, the cells may be cultured at a density of 0.5 to 2 × 10 cells per well. 5 Or about 0.5 to 2 × 10 5 Cells, 0.6–2 × 10 per well 5 or approximately 0.6 to 2 × 10 5 Cells, 0.8–2 × 10 per well 5 or approximately 0.8 to 2 × 10 5Cells, 1–2 × 10 per well 5 Or about 1 to 2 x 10 5 Cells, 0.6 x 10 per well 5 or about 0.6 x 10 5 Cells, 0.8 x 10 per well 5 or about 0.8 x 10 5 Cells, 1 x 10 per well 5 or about 1 x 10 5 Cells, 1.2 x 10 per well 5 or about 1.2 x 10 5 Cells, 1.4 x 10 per well 5 or about 1.4 x 10 5 Cells, 1.6 x 10 per well 5 Approximately 1.6 x 10 5 Cells, 1.8 x 10 per well 5 or about 1.8 x 10 5 2 x 10 cells per well 5 or about 2 x 10 5 Cells may be seeded at a density of 1 to 100 or about 1 to 100 cells per microwell, preferably about 10 to 200 cells per microwell, and more preferably about 50 to 100 cells per microwell. In one embodiment, the culture plate or vessel is any one described herein. In a specific embodiment, the culture plate or vessel is a 24-well AggreWell.
[0034] The somatic cells can be any cell type described herein, including diseased cells. Preferably, the somatic cells are human somatic cells. The somatic cells can be mature cells or cells derived from an adult that exhibit one or more detectable characteristics of mature or non-embryonic cells. The diseased cells can be cells that exhibit one or more detectable characteristics of a disease or condition, such as aneuploidy, hydatidiform mole, or Cornelia de Lange syndrome. Furthermore, the somatic cells can be those that have been genetically edited, for example, by CRISPR technology (e.g., CRISPR-Cas9, -Cas12a, -Cas13, or related CRISPR / nuclease systems).
[0035] In a preferred embodiment, the somatic cells are fibroblasts, preferably dermal fibroblasts, most preferably human fibroblasts.
[0036] In a further aspect, the present invention provides a method for producing a multi-layered cell structure or blastocyst-like structure, comprising the steps of: - culturing iPSC and iTSC cells under conditions that allow cell aggregation and aggregation to obtain multi-layered cell structures; thereby producing a multi-layered cell or blastocyst-like structure.
[0037] Preferably, the iPSCs and iTSCs are derived from human cells (e.g., obtained by reprogramming human somatic cells). Preferably, the iPSCs and iTSCs are derived from reprogramming fibroblasts.
[0038] In this aspect of the invention, iPSCs and iTSCs can be generated by any method known in the art and as further described herein.
[0039] In this aspect of the invention, the conditions that allow for cell aggregation and aggregation preferably include co-culturing iPSCs and iTSCs in any culture vessel described herein that promotes cell self-organization and aggregation. Preferably, the cells are cultured in any culture medium (e.g., blastocyst-promoting medium or iBlastoid medium) that promotes the cells to exhibit at least one characteristic of a blastocyst-like structure as described herein. Preferably, the culture medium is iBlastoid medium as shown in Table 3a.
[0040] Preferably, iPSCs and iTSCs are cultured in the same well at a ratio of 1:2.5, respectively, at 1.2 x 10 per well. 5 The cells are co-cultured as a total number of cells. It will be understood that there are 1200 microwells in one well (in the 24-well format AggreWell). Thus, cells can be seeded at a density of 10-200 or about 10-200 cells per microwell, preferably about 50-100 cells per microwell.
[0041] The present invention also provides a multi-layered cell structure or a blastocyst-like structure, preferably the multi-layered cell structure is obtained or obtainable by any of the methods as described herein. Such a multi-layered cell structure or a blastocyst-like structure may also be referred to as an in vitro-derived or in vitro-created blastoid or blastocyst-like structure or "iBlastoid." Thus, the present invention also provides an in vitro-derived or in vitro-created blastoid or blastocyst-like structure. Preferably, the in vitro-derived or in vitro-created blastoid or blastocyst-like structure is obtainable or obtained by any of the methods as described herein. In any embodiment, the multi-layered cell structure or blastocyst-like structure is a human multi-layered cell structure or a human blastocyst-like structure (or a human blastoid or iBlastoid). Preferably, the multi-layered cell structure or blastocyst-like structure contains, is derived from, or is created from only human cells.
[0042] In any of the embodiments described herein, the multi-layered cell structure or blastocyst-like structure comprises an inner cell layer and an outer cell layer, wherein the inner cell layer comprises cells exhibiting one or more characteristics of cells of the epiblast and / or primitive endoderm lineage, and the outer cell layer comprises cells exhibiting one or more characteristics of cells of the trophectoderm. Preferably, the characteristics can be determined by analysis of cell morphology, gene expression profile, activity assay, protein expression profile, surface marker profile, differentiation potential, or a combination thereof. Examples of characteristics or markers include those described herein and those known to those of skill in the art.
[0043] In any embodiment, the inner cell layer further comprises a cell mass exhibiting one or more characteristics of PE. Preferably, the cells exhibiting one or more characteristics of PE are peripheral or primarily peripheral to cells exhibiting one or more characteristics of epiblast cells.
[0044] In any aspect, EPI cells are characterized by the presence of any one or more of the markers NANOG, OCT4 (also known as POU5F1), or SOX2. In one embodiment, more cells of the multi-layered cell structure or blastocyst-like structure express OCT4 than express NANOG.
[0045] In any embodiment, EPI cells are characterized by a columnar appearance morphology.
[0046] In any embodiment, the characteristic of a TE cell is the presence of one or more of the markers CDX2 and GATA2.
[0047] In any embodiment, TE cells are characterized by a flat or elongated epithelial morphology.
[0048] In any embodiment, the characteristic of PE cells is the presence of the markers SOX17 or GATA6.
[0049] In any embodiment, the markers of the EPI, PE or TE lineage are as described in Petropoulos et al., Cell 165, 1012-1026 (2016) or as shown in Table 1 herein.
[0050] In any embodiment, the multi-layered cell structure or blastocyst-like structure may further comprise GATA6-positive cells (optionally with low or weak CDX2 staining) adjacent to OCT4-positive cells.
[0051] In any embodiment, the multi-layered cell structure or blastocyst-like structure exhibits the major morphological characteristics of an E5 to E7 preimplantation human blastocyst. Additionally, the multi-layered cell structure or blastocyst-like structure may also contain cells exhibiting one or more characteristics of epiblast, primitive endoderm, and trophectoderm cells, which are in the same or similar relative spatial arrangement as the epiblast, primitive endoderm, and trophectoderm cells, respectively, in an E5 to E7, preferably E6 to E7, human blastocyst.
[0052] In any embodiment, the multi-layered cell structure or blastocyst-like structure also comprises an acellular cavity or a blastocoel-like cavity.
[0053] In any embodiment, the multi-layered cell structure or blastocyst-like structure has the ability to form a primordial yolk sac similar to the yolk sac formed by a naturally developing embryo.
[0054] In any embodiment, the multi-layered cell structure or blastocyst-like structure has x- and y-axis diameters, x:y aspect ratios, and / or projected area that are approximately 50% to 200% of previously published measurements of human blastocysts on embryonic day 5 to 7 (E5-7) after fertilization. For example, the x- and / or y-axis diameters of the multi-layered cell structure or blastocyst-like structure are approximately 100 to 300 μm. Preferably, the x / y ratio is approximately 1. The projected area of the multi-layered cell structure or blastocyst-like structure is approximately 5,000 to 10,000 μm. 2 , about 10,000~40,000μm 2 , about 40,000μm 2 ~about 60,000μm 2, preferably about 20,000 to about 40,000 μm 2 is.
[0055] In any embodiment, the multi-layered cell structure or blastocyst-like structure comprises at least about 100 to 400 total cells or at least about 300 to about 600 cells.
[0056] In any embodiment, when cultured in IVC1 medium (as defined herein) for 1 day, followed by culture in IVC2 medium (as defined herein) from day 2 to day 4.5, the multi-layered cell structure or blastocyst-like structure attaches to a surface (such as a glass surface), a) Progression leading to increase in size, flattening and formation of growth bodies b) Increased numbers of NANOG and OCT4 / SOX2 positive cells; c) spread of CDX2 and GATA2 positive cells; d) SOX17- and GATA6-positive cells are localized around NANOG- or OCT4-positive cells; e) expression of keratin KRT7 or other trophoblast cell markers in the outer cell layer or in cells exhibiting at least one characteristic of TE cells; f) the presence of cells morphologically resembling syncytiotrophoblasts (STs) and extravillous trophoblasts (EVTs) (e.g., ST- and EVT-like cells, respectively), e.g., multinucleated phenotype and spindle-like morphology; g) the presence of cells expressing hCG (an exemplary ST marker) and MMP2 (an exemplary EVT marker); h) Presence of cells exhibiting upregulation of the ST marker CSH1 and the EVT marker ITGA1 may exhibit one or more of the following:
[0057] In another aspect, the present invention provides a culture medium (e.g., blastocyst-promoting medium or iBlastoid medium) for promoting cells to exhibit at least one characteristic of a blastocyst-like structure, comprising: - an agent that activates WNT pathway signaling, optionally a GSK-3 inhibitor; - at least one, preferably two, TGF-β inhibitors, - HDAC inhibitors, - GSK-3 inhibitors, - EGF, and - BMP4 A culture medium comprising:
[0058] In this embodiment, the activator of WNT pathway signaling, one or more TGF-β inhibitors, and HDAC inhibitor can be any one known in the art, including any one described herein.
[0059] Preferably, the culture medium comprises: - ITS-X; - L-glutamine; - N-acetyl-L-cysteine; - β-estradiol; - Progesterone; - 2-mercaptoethanol; - L-ascorbic acid; - transferrin (e.g., human), - insulin (e.g., human), - N2 supplement; and - B27 supplement Further includes:
[0060] Preferably, the progesterone, transferrin and insulin are provided in an N2 supplement further comprising putrescine and selenite as described herein.
[0061] Preferably, the B27 supplement includes biotin, DL-alpha tocopheryl acetate, DL-alpha tocopherol, vitamin A (acetate), BSA, catalase, insulin (human), superoxide dismutase, corticosterone, D-galactose, ethanolamine HCl, glutathione, L-carnitine HCl, linoleic acid, linolenic acid, progesterone, putrescine 2HCl, sodium selenite, T3 (triiodo-l-thyronine).
[0062] In any embodiment, the culture medium further comprises an antibiotic, such as penicillin-streptomycin.
[0063] In one embodiment, the culture medium comprises: - IVC1 medium, N2B27 basal medium and TSC basal medium as defined herein in a ratio of 2:1:1, respectively; - activators of WNT pathway signaling (optionally GSK-3 inhibitors), - at least one, preferably two, TGF-β inhibitors, - HDAC inhibitors, - EGF, and - BMP4 Includes:
[0064] In any aspect herein, the agent that activates WNT pathway signaling can include any small molecule that directly or indirectly activates WNT pathway signaling. In certain embodiments, the agent that activates WNT pathway signaling can be a GSK-3 inhibitor.
[0065] In any embodiment, the TGF-β pathway inhibitor is selected from SB431542 and A83-01, the histone deacetylase (HDAC) 1 inhibitor is VPA (valproic acid), and the GSK-3 inhibitor is CHIR99021.
[0066] In any embodiment, the GSK-3 inhibitor is at a concentration of 2 μM or about 2 μM, the TGF-β pathway inhibitor is at a concentration of 0.5 μM or 1 μM or about 0.5 μM or 1 μM, the histone deacetylase (HDAC) 1 inhibitor is at a concentration of 0.8 mM or about 0.8 mM, EGF is at a concentration of 50 ng / ml or about 50 ng / ml, and BMP4 is at a concentration of 10 ng / ml or about 10 ng / ml.
[0067] In any aspect or embodiment, the culture medium further comprises a ROCK inhibitor or any growth factor or kinase inhibitor capable of promoting cell survival after single cell dissociation. Preferably, the ROCK inhibitor is Y-27632. Preferably, the ROCK inhibitor is at a concentration of 10 μM or about 10 μM.
[0068] In another embodiment, the culture medium used in step c) comprises or consists of Fibroblast medium, N2B27 basal medium, TSC basal medium, IVC1 medium, IVC2 medium or Human iBlastoid medium as defined in Table 3a.
[0069] In any embodiment, the culture medium defined in step c) of any method of the invention can be any culture medium of the invention, including human iBlastoid medium as defined herein, including but not limited to, those in Table 3a.
[0070] In any embodiment, the somatic cells may have a disease genotype. For example, the somatic cells may be derived from an individual with a genetic disease, preferably an early onset disease. Examples of early onset diseases are aneuploidy, hydatidiform mole, and Cornelia de Lange syndrome.
[0071] It is also anticipated that one or more multi-layered cell structures or blastocyst-like structures (iBlastoids) of the present invention, preferably produced according to the methods of the present invention, may serve as representative models for understanding the side effects of xenobiotics and other potential environmental risk factors during the perilous state of early human development, but will also facilitate the prediction and subsequent prescription of specific drug regimens, if any, for patients preparing for pregnancy.
[0072] One or more multi-layered cell structures or blastocyst-like structures of the invention, preferably produced according to the methods of the invention, can be used as a platform for a variety of other uses, including for use in testing / developing CRISPR-based technologies, for developing / refinement of in vitro attachment assays, and for studying embryonic development and the development of extraembryonic tissues (such as the placenta).
[0073] In another aspect, the present invention provides a method for identifying an agent capable of modulating blastocyst development (optionally to improve procedures associated with in vitro fertilization techniques) and / or activity, comprising: - contacting the multi-layered cell structure or blastocyst-like structure of the invention, preferably produced according to the present invention, with a candidate drug; - comparing the development and / or activity of the multi-layered cell structures or blastocyst-like structures after contact with the agent with the development and / or activity of the multi-layered cell structures or blastocyst-like structures without the agent; wherein the effect of the agent on the development and / or activity of the multi-layered cell structure or blastocyst-like structure is greater than the development of the multi-layered cell structure or blastocyst-like structure in the absence of the agent by a predetermined level indicates that the agent modulates the development and / or activity of trophoblast cells.
[0074] In another aspect, the present invention provides a method for obtaining a compound or particle produced by a multi-layered cell structure or blastocyst-like structure, the method comprising culturing a multi-layered cell structure or blastocyst-like structure according to the present invention and isolating a compound or particle secreted by the cells from the culture medium, thereby obtaining the compound produced by the multi-layered cell structure or blastocyst-like structure. The compound may be a hormone or growth factor. The particle may be an extracellular vesicle such as an exosome.
[0075] One or more multicellular structures or blastocyst-like structures of the present invention, preferably according to the method described herein, can be used to create chimeric organs or organoids.Thus, the present invention also provides the use of one or more multicellular structures or blastocyst-like structures of the present invention, preferably according to the method described herein, to create chimeric organs or organoids.Such chimeric organoids can be useful for the research of various pathologies or diseases or for the screening of therapeutic agents.
[0076] In another aspect, the present invention also relates to a kit for producing a multi-layered cell structure or a blastocyst-like structure as disclosed herein. In some embodiments, the kit comprises somatic cells, reprogramming factors, and one or more culture media as disclosed herein. Preferably, the kit can be used to produce a multi-layered cell structure or a blastocyst-like structure. Preferably, the kit can be used with somatic cells that are fibroblasts. In some embodiments, the kit further comprises instructions for reprogramming somatic cells into a multi-layered cell structure or a blastocyst-like structure according to a method as disclosed herein. Preferably, the present invention provides a kit for use in the method of the present invention described herein.
[0077] In a further aspect, the present invention provides a cell or population of cells derived from, isolated from or obtained from one or more multicellular or blastocyst-like structures of the present invention, preferably produced according to the methods described herein, which cell or population of cells may exhibit one or more characteristics of the EPI lineage, or one or more characteristics of the PE lineage, or one or more characteristics of the TE lineage.
[0078] Typically, a cell or population of cells derived from, isolated from or obtained from a multicellular or blastocyst-like structure of the invention, preferably produced according to the method of the invention, has the capacity for self-renewal, in other words, a cell or population of cells derived from, isolated from or obtained from a multicellular or blastocyst-like structure of the invention, preferably produced according to the method of the invention, is characterized in that it can be maintained in culture.
[0079] In another aspect, the present invention also provides the organoid that is derived from or obtained from the cell or cell group described herein.Organoid can also comprise the chimeric organoid that is derived from the multicellular structure or blastocyst-like structure that is produced according to the method of the present invention, preferably as described herein.
[0080] As used herein, unless the context otherwise requires, the term "comprise" and variations of this term, such as "comprises", "comprises" and "included", are not intended to exclude further additives, components, integers or steps.
[0081] Further aspects of the invention and further embodiments of the aspects described in the preceding paragraphs will become apparent from the following description, given by way of example and referring to the accompanying drawings, in which: [Brief explanation of the drawings]
[0082] [Figure 1]Creation of human iBlastoids by reprogramming. a) Experimental design for reprogramming and iBlastoid derivation. b) Phase contrast images of iBlastoids (n=5). Scale bar, 50 μm. c) Phase contrast and immunostained images of iBlastoids for NANOG (n=5). Scale bar, 50 μm. d-h: Measurements of the x- and y-axis diameters, x / y aspect ratios, and projected areas of iBlastoids compared to human blastocysts (n=18) (Shahbazi, M. et al. Nat. Cell Biol. 18, 700-708 (2016); Blakeley, P. et al. Development 142, 3613 (2015); Petropoulos, S. et al. Cell 165, 1012-1026 (2016); Xiang, L. et al. Nature 577, 537-542 (2020); Qin, H. et al. Cell Rep. 14, 2301-2312 (2016); Liu, L. et al. Nat. Commun. 10, 364 (2019); Durruthy-Durruthy, J. et al. Dev. Cell 38, 100-115 (2016); Fogarty, NME et al. Nature 550, 67-73 (2017)) (n=8). i, Estimated total cell number in iBlastoids (n=14). j, 3D and 2D representations of iBlastoids stained for CDX2 and NANOG (n=5). Scale bar, 20 μm. k-l, Representative DIC representations of iBlastoids and CDX2 and NANOG immunostaining (n=5), illustrating the blastocoel-like cavity as indicated by the arrow. Scale bar, 10 μm. m, Immunostaining of iBlastoids for GATA2, OCT4, and SOX2 (n=3). Scale bar, 20 μm. n, iBlastoid stained for GATA2, NANOG, and SOX17 with an ICM-like compartment - zoom shows SOX17-positive PE-like cells (n=2). o, iBlastoid stained for CDX2, OCT4, and GATA6 with ICM-like compartments - zoom shows low CDX2 and GATA6 positive PE-like cells (n=2). Scale bar in n-o = 10 μm.p-q, Representative images of iBlastoids stained for F-actin and NANOG with EPI-like and TE-like cells, zoomed in (q) to highlight their morphological differences (n=2). r, 3D segmentation of the iBlastoid in (p) based on F-actin (light blue) and NANOG (orange). Scale bars in p-r = 10 μm for the whole iBlastoid and 2 μm for the zoomed in ICM. s, F-actin, OCT4, and KRT8 co-staining, n=2. [Figure 2] Generation and characterization of iBlastoids. a) scRNA-seq analysis of day 21 reprogramming intermediates, showing the presence of EPI, TE, and PE-like populations. b) Phase-contrast images of iBlastoid formation over time (n=5). Scale bar, 100 μm. c) Quantification of iBlastoids with cavity formation (n=100). Scale bar, 20 μm. d) Representative phase-contrast images of refractory HDFa adhered to the edge of a microwell during iBlastoid formation (n=2), grown in fibroblast medium with a classic fibroblast morphology. Scale bar, 100 μm. e) 3D and 2D representations of iBlastoids stained for CDX2 and NANOG (n=5). Scale bar, 20 μm. f) iBlastoids stained for GATA2, NANOG, and SOX17 (n=2). g, iBlastoids stained for CDX2, OCT4, and GATA6 (n=2). Scale bar for f-g, 20 μm. h, Quantification of different pre-existing cell populations in day 21 reprogrammed cells; n=3. i, Criteria used to score iBlastoids. j, Phase contrast images of iBlastoids included in the scoring, n=24. Scale bar, 100 μm. k, Mean ICM and TE scores for iBlastoids in (i) by (h), n=24. [Figure 3]iBlastoid single-cell transcriptome profiling. a, Experimental design of a scRNA-seq experiment using iBlastoid. b, Expression of EPI markers (POU5F1 and NANOG), TE markers (CDX2 and GATA2), and PE markers (SOX17 and GATA6) for 6858 cells from the iBlastoid scRNA-seq library. c, Per-cell expression scores for EPI, TE, and EPI signatures in a UMAP of the iBlastoid scRNA-seq dataset. d, Unsupervised clustering of the iBlastoid dataset with assigned cluster names. e, UMAP projection of the merged dataset showing iBlastoid EPI, TE, and PE cells along with EPI, TE, and PE cells from blastocysts (Blakeley and Petropoulos). f, Per-cell expression scores for EPI, TE, and PE signatures in the merged dataset. g, Unsupervised clustering of the merged dataset with assigned cluster names. h, Proportion of cells within each integrated cluster for iBlastoid and human blastocyst datasets (Blakeley and Petropoulos) by their respective original cell IDs before integrated analysis. i, Pearson correlation analysis between iBlastoid EPI, TE, and PE clusters and annotated EPI, TE, and PE clusters from blastocysts (Blakeley and Petropoulos). j, k, Per-cell expression scores of defined wall TE and polar TE signatures in iBlastoid scRNA-seq TE clusters. l, Post-binning subtype scores of wall TE and polar TE signatures along UMAP component 1. m, Immunostaining of iBlastoid for CCR7, n=4. Scale bar, 20 μm. n, CCR7 fluorescence intensity of iBlastoid polar TE and wall TE, n=4. The line within each box represents the median, and the whiskers represent the maximum and minimum values, respectively. [Figure 4]scRNA-seq pipeline and quality control. a, scRNA-seq analysis strategy (see Methods for details). b, UMAP representation of donor cell distribution for iBlastoids. c, UMAP representation of cell cycle for iBlastoid scRNA-seq libraries. d, Expression of Sendai-KLF4, Sendai-KOS, and Sendai-MYC in iBlastoids. e, Expression of EPI markers (POU5F1 and NANOG), TE markers (CDX2 and GATA2), and PE markers (SOX17 and GATA6) for the Petropoulos scRNA-seq library (Petropoulos). f, g, Expression of non-reprogramming signatures and IFI27 expression in UMAP of the iBlastoid dataset. [Figure 5] Scoring of defined E5-7 EPI, TE, and PE signatures for blastocysts and iBlastoids. a, Defined EPI, TE, and PE signatures for developmental ages E5, E6, and E7 on the Petropoulos scRNA-seq dataset (Petropoulos). b, Defined EPI, TE, and PE signatures for developmental ages E5, E6, and E7 on the iBlastoid scRNA-seq dataset. [Figure 6]scRNA-seq analysis of iBlastoid and blastocyst datasets. a, Cell proportions for each donor across all assigned clusters. b, Heatmap showing gene expression profiles for each assigned cluster in the iBlastoid scRNA-seq dataset (top 10 genes for each). c, UMAP projection showing cell distribution for iBlastoid and blastocysts (Blakeley and Petropoulos) in the combined dataset. d, Expression of EPI markers (POU5F1 and NANOG), TE markers (CDX2 and GATA2), and PE markers (SOX17 and GATA6) for the combined dataset of iBlastoid and E5-7 blastocysts (Blakeley and Petropoulos). e, Pearson correlation analysis between iBlastoid EPI, TE, and PE clusters and annotated EPI, TE, and PE clusters from blastocysts (Blakeley and Petropoulos). [Figure 7] Modeling human in vitro implantation using iBlastoids. a, Representative phase-contrast images (n=5) of iBlastoids at days 1, 3, and 4.5 of attachment. Scale bar, 100 μm. b, GATA2, NANOG, and SOX17 co-staining, n=2. c, CDX2, OCT4, and GATA6 co-staining, n=2. d, F-actin, OCT4, and aPKC co-staining; arrows indicate primitive amniotic cavity-like cavities; n=2. e, KRT7 and NANOG co-staining, n=4. f, F-actin and NANOG co-staining; arrows indicate epiblast-like cells and presumptive ST and EVT; n=2. g, MMP2 and hCG co-staining, n=2. Scale bar, 50 μm; 10 μm for enlarged view. h, qRT-PCR analysis of ST and EVT markers in attached iBlastoids; mean ± sem, n=5. i, hCG protein levels detected by hCG ELISA using conditioned medium collected from adherent iBlastoids, mean ± sem, n = 4. [Figure 8]Determination of epiblast development in attached iBlastoids. a) Schematic of the experimental design for the iBlastoid in vitro attachment assay. b) Time-course qRT-PCR analysis of primitive streak markers (TBXT, Eomes, and MIXL1) in iBlastoids up to day 5 of the attachment assay. Positive controls for TBXT, Eomes, and MIXL1 were generated using a published mesoderm differentiation protocol (Lam et al., 2014, J. Am. Soc. Nephrol) (n=6). c) Attached iBlastoids stained for CDX2 and NANOG (n=5). d) Attached iBlastoids stained for GATA2, OCT4, and SOX2 (n=3). e) Magnified images of attached iBlastoids stained for NANOG and SOX17 (n=2). f) Magnified images of attached iBlastoids stained for OCT4 and GATA6 (n=2). Scale bars for c-f, 100 μm. g, Z-section series of attached iBlastoids stained for F-actin, OCT4, and aPKC; zoomed-in images show the amniotic cavity, n=2. Scale bar, 20 μm. h, Immunostaining of iBlastoids, day 1 attached iBlastoids, and day 3 attached iBlastoids for F-actin, OCT4, and aPKC, n=2. Scale bar, 20 μm. The appearance of the amniotic cavity-like cavity is marked with an arrow. i, Immunostaining of iBlastoids and attached iBlastoids for KRT7 and NANOG, n=4. j, Adherent iBlastoids stained for F-actin and NANOG, n=2. k, Immunostaining of iBlastoids and attached iBlastoids for MMP2 and hCG, n=2. [Figure 9](a) Naive iPSCs containing a GFP reporter. Scale bar: 100 μm. (b): iTSCs containing an mCherry reporter. Scale bar: 100 μm. (c): Aggregates of naive iPSCs and iTSCs. Scale bar: 20 μm. (d): Aggregates of naive iPSCs only. Scale bar: 20 μm. (e): Aggregates of iTSCs only. Scale bar: 20 μm. (f): Immunostaining of aggregates of naive iPSCs and iTSCs, naive iPSCs only, and iTSCs only using the pluripotency marker OCT4 and the TSC marker KRT7. Scale bar: 20 μm. (g): Immunostaining of aggregates of naive iPSCs only using the pluripotency marker NANOG and the TSC marker CDX2. Scale bar: 20 μm. [Figure 10] Characterization of attached iBlastoids. qRT-PCR analysis of ST markers (SDC1, HSD3B1) and EVT markers (ITGA5, FN1) in attached iBlastoids, mean ± sem, n=5. [Figure 11] Determination of the proportion of EPI-, TE-, and PE-like cells during reprogramming in other culture conditions. Day 8 reprogrammed intermediates were transferred to a) NACL medium, b) PA medium, and c) t2iLGo medium, and the proportion of EPI-, TE-, and PE-like cells was determined on day 21 of reprogramming. Markers selected were GATA3 for TE-like cells, GATA6 for PE-like cells, and KLF17 for EPI-like cells. Scale bar, 100 μm. [Figure 12]21-day-old reprogrammed cells generated from human fibroblasts by mRNA-mediated reprogramming. a, Immunostaining analysis of OCT4, GATA6, and CDX2 for 21-day-old reprogrammed cells generated from 4×OKSMNL mRNA transfection of human fibroblasts. b, Immunostaining analysis of GATA2, NANOG, and SOX17 for 21-day-old reprogrammed cells generated from 4×OKSMNL mRNA transfection of human fibroblasts. c, Immunostaining analysis of OCT4, GATA6, and CDX2 for 21-day-old reprogrammed cells generated from 6×OKSMNL mRNA transfection of human fibroblasts. d, Immunostaining analysis of GATA2, NANOG, and SOX17 for 21-day-old reprogrammed cells generated from 6×OKSMNL mRNA transfection of human fibroblasts. [Figure 13] Day 21 reprogrammed cells generated from human mesenchymal stem cells (hMSCs) by Sendai virus-mediated reprogramming. a) Immunostaining analysis of OCT4, GATA6, and CDX2 for day 21 reprogrammed cells generated from hMSCs. b) Immunostaining analysis of GATA2, NANOG, and SOX17 for day 21 reprogrammed cells generated from hMSCs. [Figure 14]Day 18 and day 21 reprogrammed cells generated from human peripheral blood mononuclear cells (hPBMCs) by Sendai virus-mediated reprogramming. a, Immunostaining analysis of OCT4, GATA6, and CDX2 for day 18 reprogrammed cells generated from hPBMCs in StemPro34 medium. b, Immunostaining analysis of OCT4, GATA6, and CDX2 for day 21 reprogrammed cells generated from hPBMCs in StemPro34 medium. c, Immunostaining analysis of OCT4, GATA6, and CDX2 for day 18 reprogrammed cells generated from hPBMCs in StemPro34 medium supplemented with 10% FBS. d, Immunostaining analysis of GATA2, NANOG, and SOX17 for day 18 reprogrammed cells generated from hPBMCs in StemPro34 medium supplemented with 10% FBS. e, Immunostaining analysis of OCT4, GATA6, and CDX2 on day 21 reprogrammed cells generated from hPBMCs in StemPro34 medium supplemented with 10% FBS. f, Immunostaining analysis of GATA2, NANOG, and SOX17 on day 21 reprogrammed cells generated from hPBMCs in StemPro34 medium supplemented with 10% FBS. DETAILED DESCRIPTION OF THE INVENTION
[0083] Reference will now be made in detail to specific embodiments of the invention. While the invention will be described in conjunction with the embodiments, it will be understood that the intention is not to limit the invention to those embodiments. On the contrary, the invention is intended to cover all alternatives, modifications, and equivalents that may be included within the scope of the present invention as defined by the claims.
[0084] Those skilled in the art will recognize many methods and materials similar or equivalent to those described herein, which could be used in the practice of the present invention. The present invention is in no way limited to those methods and materials described. It will be understood that the invention disclosed and defined herein extends to any and all alternative combinations of two or more of the individual features mentioned or apparent from the specification or drawings. All of these different combinations constitute various alternative aspects of the invention.
[0085] For purposes of interpreting this specification, terms used in the singular shall also include the plural and vice versa.
[0086] The present inventors have developed a novel culture method derived from the unexpected discovery that human somatic cells (e.g., fibroblasts) can be directly reprogrammed into human multilayered cellular or blastocyst-like structures (hereinafter also referred to as iBlastoids) that faithfully recapitulate the morphology, spatial interactions, and molecular composition of human blastocysts. Furthermore, iBlastoids can mimic many aspects of early human embryonic development, as verified by in vitro attachment assays using human embryonic adherent cultures. Thus, the present inventors report for the first time the generation of human iBlastoids, which represent a unique, experimentally tractable system for modeling and investigating the complex cellular and molecular interactions that occur during early human embryonic development.
[0087] cell The methods of the invention involve the use of reprogrammed somatic cells, which exhibit epiblast (EPI), trophectoderm (TE), and primitive endoderm (PE) transcriptional signatures, thereby creating a multi-layered cellular structure resembling a blastocyst. As described further herein, it will be understood that in certain embodiments, the methods of the invention can include approaches that start with somatic cells prior to reprogramming and obtaining reprogrammed somatic cells exhibiting epiblast (EPI), trophectoderm (TE), and primitive endoderm (PE) transcriptional signatures. In such cases, the methods may require an initial step of initiating somatic cell reprogramming according to methods further described herein. In alternative embodiments, the methods of the invention can involve starting with reprogrammed intermediates (e.g., cells cultured under conditions that promote reprogramming toward a pluripotent state, but which may or may not have completed reprogramming toward a fully pluripotent state, and are therefore referred to as reprogrammed intermediates).
[0088] Somatic cells can be healthy somatic cells or diseased cells, or can be derived from healthy individuals or individuals with or suspected of having one or more medical conditions or diseases. Somatic cells can also be from deceased individuals. Somatic cells can be mature cells or cells from adults that exhibit one or more detectable characteristics of mature or non-embryonic cells. Diseased somatic cells can be cells that exhibit one or more detectable characteristics of a disease or condition.
[0089] Somatic cells for use in the present invention may be derived from iPSCs or other embryonic or adult stem cells, or may be derived from tissue explants from a subject. In a particular example, somatic cells for use in the present invention contain an inducible expression cassette encoding factors for reprogramming towards a dedifferentiated or pluripotent state, are differentiated from iPSCs or other embryonic or adult stem cells, and then dedifferentiated through induction of expression of the expression cassette.
[0090] The population of somatic cells will preferably comprise a homogeneous population of cells (i.e., a population of somatic cells of the same type, such as a homogeneous population of fibroblasts or a homogeneous population of keratinocytes, where the cell population does not contain somatic cells of another cell type). It will be appreciated that to obtain such a homogeneous population of cells, it may be necessary to subject the population of cells (e.g., obtained from an individual) to culture and other steps necessary to isolate the somatic cells of interest from a heterogeneous population of cells, so that a homogeneous population of cells is obtained.
[0091] In certain embodiments, the population of somatic cells used to reprogram into cells exhibiting epiblast (EPI), trophectoderm (TE) and primitive endoderm (PE) transcriptional signatures does not include embryonic stem cells, and preferably does not include expanded (or increased) pluripotent stem cells.
[0092] In a preferred embodiment, the somatic cells are fibroblasts (preferably dermal fibroblasts), keratinocytes (preferably epidermal keratinocytes), monocytes, endothelial cells, or mesenchymal stem cells. Preferably, the somatic cells for use in the methods of the present invention comprise only fibroblasts. Alternatively, the somatic cells for use in the methods of the present invention may be peripheral blood mononuclear cells (PBMCs), preferably human. Alternatively, the somatic cells for use in the methods of the present invention may be mesenchymal stem cells (MSCs), preferably human. Morphological and gene expression markers characteristic of somatic cells will be known to those skilled in the art. Consequently, it is within the skill of the art to test for and observe a decrease in markers characteristic of somatic cells during the course of the methods of the present invention. In a specific example, when the somatic cells are dermal fibroblasts, the morphological characteristics include a flattened mesenchymal morphology, and the markers include CD13 (ANPEP), CD44, TWIST1, and ZEB1.
[0093] Keratinocyte markers include keratin 1, keratin 14, and involucrin, and the cell morphology is a cobblestone appearance. Endothelial cell markers include CD31 (Pe-CAM), VE-cadherin, and VEGFR2, and the cell morphology may be capillary-like. Epithelial cell markers include cytokeratin 15 (CK15), cytokeratin 3 (CK3), involucrin, and connexin 4. Preferably, the observed morphology is a cobblestone appearance. Hematopoietic stem cell markers may include CD45 (pan-hematopoietic marker), CD19 / 20 (B cell marker), CD14 / 15 (myeloid), CD34 (progenitor / SC marker), and CD90 (SC). Mesenchymal stem cell markers include CD13, CD29, CD90, CD105, CD10, and CD45.
[0094] As used herein, the term "stem cell" refers to a cell that is not terminally differentiated, i.e., which has the potential to differentiate into other cell types with more specialized functions. The term encompasses embryonic stem cells, fetal stem cells, adult stem cells, or committed / progenitor cells.
[0095] As used herein, "somatic cell" refers to a terminally differentiated cell. As used herein, the term "somatic cell" refers to any cell that forms the body of an organism, as opposed to a germline cell. In mammals, germline cells (also known as "gametes") are the sperm and eggs that fuse at fertilization to produce the cell from which the entire mammalian embryo develops, called a zygote. All other cell types in the mammalian body—apart from sperm and eggs, the cells from which they are produced (gametocytes), and undifferentiated stem cells—are somatic cells: internal organs, skin, bone, blood, and connective tissue are all made up of somatic cells. In some embodiments, the somatic cell is a "non-embryonic somatic cell," which refers to a somatic cell that is not present in or obtained from an embryo and is not obtained by in vitro propagation of such a cell. In some embodiments, the somatic cell is an "adult somatic cell," which refers to a cell that is present in or obtained from an organism other than an embryo or fetus, or a cell that is obtained by in vitro propagation of such a cell. Somatic cells can be immortalized to provide an unlimited supply of cells, for example, by increasing the levels of telomerase reverse transcriptase (TERT). For example, TERT levels can be increased by increasing transcription of TERT from an endogenous gene or by introducing a transgene through any gene delivery method or system.
[0096] Differentiated somatic cells are suitable for use in the methods of the present invention, including cells from fetal, neonatal, juvenile, or adult primate individuals, including humans. Suitable somatic cells include, but are not limited to, bone marrow cells, epithelial cells, endothelial cells, fibroblasts, peripheral blood mononuclear cells, hematopoietic cells, keratinocytes, hepatocytes, intestinal cells, mesenchymal cells, bone marrow progenitor cells, and spleen cells. Alternatively, somatic cells may be cells capable of proliferating and differentiating into other cell types, including blood stem cells, muscle / bone stem cells, brain stem cells, and liver stem cells. Suitable somatic cells contain genetic material encoding transcription factors and are competent to incorporate transcription factors, or can be made competent using methods generally known in the scientific literature. Methods for enhancing uptake may vary depending on the cell type and expression system. Exemplary conditions used to prepare competent somatic cells with suitable transduction efficiency are well known to those of skill in the art. Starting somatic cells may have a doubling time of approximately 24 hours.
[0097] The term "isolated cell," as used herein, refers to a cell that has been removed from the organism in which it was originally found, or the progeny of such a cell. Optionally, the cell has been cultured in vitro, for example, in the presence of other cells. Optionally, the cell is later introduced into a second organism, or reintroduced into the organism from which it (or its descendants) was isolated.
[0098] Multilayered cell structure or blastocyst-like structure The present invention provides a multi-layered cell structure or blastocyst-like structure or a composition comprising the same. Preferably, the multi-layered cell structure is obtained or obtainable by any of the methods as described herein. Such multi-layered cell structures or blastocyst-like structures may also be referred to as in vitro-derived or in vitro-created blastoids or blastocyst-like structures or "iBlastoids."
[0099] It will be appreciated that the multi-layered cell structures or blastocyst-like structures of the present invention can be characterized by a number of structural and functional attributes, including those further described below. Importantly, and as detailed below, while the structures of the present invention exhibit the major morphological characteristics of E5-7 human blastocysts, the structures are also characterized by attributes that distinguish them from naturally developing human blastocysts, such as the absence of the zona pellucida, which is present in naturally developing blastocysts but not in the structures of the present invention. Thus, the in vitro-derived or in vitro-created blastocyst structures of the present invention can be clearly distinguished from naturally developing blastocysts.
[0100] In any embodiment, the multi-layered cell structure or blastocyst-like structure comprises an inner cell layer and an outer cell layer, wherein the inner cell layer comprises cells exhibiting one or more characteristics of cells of the epiblast and / or primitive endoderm lineage, and the outer cell layer comprises cells exhibiting one or more characteristics of cells of the trophectoderm lineage. Preferably, the characteristics may be determined by analysis of cell morphology, gene expression profile, activity assay, protein expression profile, surface marker profile, differentiation potential, or a combination thereof. Examples of characteristics or markers include those described herein and known to those skilled in the art. The multi-layered cell structure or blastocyst-like structure may or may not have a cavity / blastocoel.
[0101] In any embodiment, the inner cell layer further comprises a cell mass exhibiting one or more characteristics of PE. Preferably, the cells exhibiting one or more characteristics of PE are peripheral or primarily peripheral to cells exhibiting one or more characteristics of epiblast cells.
[0102] In any embodiment, the inner cell layer is an inner cell mass-like tissue that behaves essentially like a naturally formed inner cell mass.
[0103] In any embodiment, the outer cell layer is a trophectoderm-like tissue that behaves essentially like naturally formed trophectoderm.
[0104] The multi-layered cell structure or blastocyst-like structure may also be referred to as an artificial blastocyst, which comprises trophectoderm-like tissue surrounding a blastocoel and inner cell mass-like tissue.
[0105] In any embodiment, the population of cells exhibiting transcriptional signatures of the epiblast (EPI), trophectoderm (TE) and / or primitive endoderm (PE) lineages preferably exhibits transcriptional signatures of each of the epiblast (EPI), trophectoderm (TE) and primitive endoderm (PE) lineages.
[0106] In any aspect, EPI cells are characterized by the presence of any one or more of the markers NANOG, OCT4 (also known as POU5F1), or SOX2. In one embodiment, more cells of the multi-layered cell structure or blastocyst-like structure express OCT4 than NANOG.
[0107] In any embodiment, EPI cells are characterized by a columnar appearance morphology.
[0108] In any embodiment, the characteristic of a TE cell is the presence of one or more of the markers CDX2 and GATA2.
[0109] In any embodiment, TE cells are characterized by a flat or elongated epithelial morphology.
[0110] In any embodiment, the characteristic of PE cells is the presence of the markers SOX17 or GATA6.
[0111] [Table 1]
[0112] In any embodiment, the multi-layered cell structure or blastocyst-like structure may further comprise GATA6-positive cells (optionally with low or weak CDX2 staining) adjacent to OCT4-positive cells.
[0113] In any embodiment, the multilayered cell structure or blastocyst-like structure exhibits the major morphological characteristics of an E5-7, preferably E6-7, human blastocyst. The major morphological characteristics of E5-7 and E6-7 human blastocysts are known to those skilled in the art. Such characteristics may include a spherical or approximately spherical layered cell aggregate or structure comprising at least two radially arranged layers, and including an inner cell layer (as defined herein) and an outer cell layer (as defined herein), along with a zona pellucida and a fluid-filled cavity called the blastocoel. Blastocysts are approximately 0.1-0.2 mm in diameter and typically contain approximately 200-300 cells. Generally, cells exhibiting one or more characteristics of cells of the epiblast and / or primitive endoderm lineage are present in a single mass located on the interior of the aggregate or structure, while cells exhibiting one or more characteristics of cells of the trophectoderm lineage are present on the exterior.
[0114] For further characteristics and properties of human blastocysts, see, for example, Blakeley, P. et al. (2015) Development 142, 3613; Petropoulos, S. et al. (2016) Cell 165, 1012-1026; Shahbazi, M. et al. (2016) Nat. Cell Biol. 18, 700-708; Xiang, L. et al. (2020) Nature 577, 537-542; Qin, H. et al. (2016) Cell Rep. 14, 2301-2312; Liu, L. et al. (2019) Nat. Commun. 10, 364; Durruthy-Durruthy, J. et al. (2016) Dev. Cell 38, 100-115; Fogarty, NME et al. (2017) Nature 550, 67-73.
[0115] Additionally, the multi-layered cell structure or blastocyst-like structure may also contain cells exhibiting one or more characteristics of epiblast, primitive endoderm, and trophectoderm cells, which are in the same or similar relative spatial arrangement as the epiblast, primitive endoderm, and trophectoderm cells, respectively, in an E5-7, preferably E6-7, human blastocyst. As used herein, "same or similar relative spatial arrangement" compared to a human blastocyst shall be interpreted to mean having at least two radially positioned layers and including an inner cell layer (as defined herein) and an outer cell layer (as defined herein). While there may be more than two cell layers, the essence is generally that cells exhibiting one or more characteristics of epiblast and / or primitive endoderm lineage cells are present in a single mass located on the interior of the aggregate or structure, while those exhibiting one or more characteristics of trophectoderm lineage cells are present on the exterior. In other words, the outer layer of cells in the construct are typically TE cells (and express TE markers such as CDX2 and GATA2), while cells that will direct the epiblast (and express markers such as NANOG and 4 and SOX2) are found in an ICM-like compartment within the construct.
[0116] In some embodiments, the multi-layered cell structure or blastocyst-like structure also contains an acellular cavity or a blastocoel-like cavity. The multi-layered cell structure or blastocyst-like structure may undergo hollowing, thereby allowing the formation of a blastocoel. After the formation of the blastocoel-like cavity, an inner cell mass-like tissue may be located in one portion of the inner cavity, while the remaining portion of the cavity is filled with fluid.
[0117] The multi-layered cell structures or blastocyst-like structures produced by the methods of the present invention generally differ from naturally occurring human blastocysts in that the structures of the present invention do not form or contain a zona pellucida.
[0118] As used herein, the term "zona pellucida" refers to the glycoprotein layer that surrounds the cell membrane of a mammalian oocyte. After fertilization of the oocyte, the zona pellucida remains intact; thus, naturally occurring blastocysts contain the zona pellucida until about 5 days after fertilization, when the blastocyst undergoes so-called "zona hatching," in which the zona pellucida degenerates and breaks down as part of implantation.
[0119] The constructs of the present invention can also be differentiated from naturally occurring blastocysts in that they may contain cells with a general gene signature not found in cells of a blastocyst, typically a mixed gene expression profile, such as cells expressing genes characteristic of both PE and TE, both PE and EPI, both TE and EPI, or a combination of PE, TE, and EPI. In other words, some cells in the constructs of the present invention may have a mixed transcriptional signature characteristic of more than one lineage. In other words, one or more individual cells may have a mixed transcriptional signature characteristic of more than one lineage. The transcriptional signatures associated with each lineage are further described herein, for example, in
[0117] -
[0122] above and in Table 1.
[0120] In any embodiment, the multi-layered cell structure or blastocyst-like structure has x-axis and y-axis diameters, x:y aspect ratios, and / or projected area equivalent to previously published measurements of human blastocysts on embryonic day 5 to 7 (E5-7) after fertilization. For example, the x-axis and / or y-axis diameters of the multi-layered cell structure or blastocyst-like structure are about 100 to about 300 μm. Preferably, the x / y axis ratio is about 1. The projected area of the multi-layered cell structure or blastocyst-like structure is about 5,000 to about 10,000 μm. 2 , about 10,000~40,000μm 2 , about 40,000~60,000μm 2 , preferably about 20,000 to about 40,000 μm 2 is.
[0121] As used herein, x-axis and y-axis diameters or x:y aspect ratios that are "equivalent" to published measurements of E5-7 human blastocysts can include x-axis and y-axis diameters or x:y aspect ratios that are about 50% to 200% of the published measurements, preferably at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 110%, at least about 1200%, at least about 120%, at least about 130%, at least about 140%, at least about 150%, at least about 160%, at least about 170%, at least about 180%, at least about 190%, or at least about 200% of the published measurements.
[0122] As used herein, a projected area "equivalent" to a previously published measurement for E5-7 human blastocysts can include a projected area that is about 50% to 200% of the previously published measurement for human blastocysts. Preferably, the equivalent projected area is between 5,000 and about 40,000 μm 2 In other words, the equivalent projected area is from about 5,000 to about 10,000 μm. 2 , about 10,000~40,000μm 2 , about 40,000μm 2 ~about 60,000μm 2 , preferably about 20,000 to about 40,000 μm 2 The area may be.
[0123] In the context of the present invention, a multi-layered cell structure or blastocyst-like structure is a layered cell aggregate or structure comprising at least two radially positioned layers. Preferably, it is a spherical or approximately spherical cell aggregate or structure comprising an inner cell layer (as defined herein) and an outer cell layer (as defined herein). There may be more than two cell layers, but generally the essence is that cells exhibiting one or more characteristics of cells of the epiblast and / or primitive endoderm lineage are present in a single mass located on the inside of the aggregate or structure, while cells exhibiting one or more characteristics of cells of the trophectoderm are present on the outside.
[0124] In any embodiment, the multi-layered cell structure or blastocyst-like structure comprises about 100-400 total cells.
[0125] In a preferred embodiment, the present invention provides an in vitro-derived or in vitro-created blastocyst or blastoid structure (i.e., a multi-layered cell structure or a blastocyst-like structure) having one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, or thirteen of the following characteristics: spherical or nearly spherical layered cell aggregates or structures comprising at least two radially positioned layers, and including an inner cell layer and an outer cell layer, and lacking a zona pellucida; an inner cell layer containing cells that exhibit one or more characteristics of epiblast (EPI) cells, characterized by the presence of one or more of the markers NANOG, OCT4 (also known as POU5F1) or SOX2 and a columnar appearance; an inner cell layer that also contains a cell mass exhibiting one or more characteristics of the primitive endoderm (PE) lineage, where the cells exhibiting one or more characteristics of the PE are surrounding or primarily surrounding cells exhibiting one or more characteristics of cells of the epiblast; PE cells are characterized by the presence of the markers SOX17 or GATA6. an outer cell layer containing cells that exhibit one or more characteristics of cells of the trophectoderm (TE), the characteristics of TE cells being the presence of one or more of the markers CDX2 and GATA2 and a flattened or elongated epithelial morphology; Diameter of about 0.1-0.2mm; ·About 100~400 cells; · More cells in multi-layered cell structures or blastocyst-like structures express OCT4 than NANOG; GATA6-positive cells adjacent to OCT4-positive cells (optionally with low or weak CDX2 staining); The x-axis and / or y-axis diameter of the multilayered cell structure or blastocyst-like structure is about 100 to about 300 μm; x / y axis ratio of approximately 1; ·Approx. 5,000~10,000μm 2 , about 10,000~40,000μm 2 , about 40,000μm 2 ~about 60,000μm 2 , preferably about 20,000 to about 40,000 μm 2 Projected area of; Optionally, a fluid-filled cavity called the blastocoel; and Optionally, cells exhibiting one or more characteristics of cells of the epiblast and / or primitive endoderm lineage are present in a single mass located on the interior side of the aggregate or structure, while cells exhibiting one or more characteristics of cells of the trophectoderm are present on the exterior side.
[0126] The multi-layered cell structures or blastocyst-like structures of the present invention and / or obtained according to the methods of the present invention typically exhibit characteristics that mimic many aspects of early human embryonic development. In certain embodiments, the structures mimic the characteristics of a human embryo in an in vitro attachment assay that can be used to study embryo implantation. For example, when cultured in IVC1 medium (as defined herein) for 1 day, followed by culture in IVC2 medium (as defined herein) from day 2 to day 4.5, the multi-layered cell structures or blastocyst-like structures exhibit: i) Increase in size, progression to flattening and formation of outgrowths; j) Increased numbers of NANOG and OCT4 / SOX2 positive cells; k) spread of CDX2 and GATA2 positive cells; l) SOX17- and GATA6-positive cells are localized around NANOG- or OCT4-positive cells; m) expression of keratin KRT7 or other trophoblast cell markers in the outer cell layer or in cells exhibiting at least one characteristic of TE cells; n) the presence of cells morphologically resembling syncytiotrophoblasts (STs) and extravillous trophoblasts (EVTs) (e.g., ST- and EVT-like cells, respectively), e.g., multinucleated phenotype and spindle-like morphology; o) the presence of cells expressing hCG (an exemplary ST marker) and MMP2 (an exemplary EVT marker); and p) The presence of cells exhibiting upregulation of the ST marker CSH1 and the EVT marker ITGA1 may exhibit one or more of the following:
[0127] It will be appreciated that "increase," as used herein, whether with respect to an increase in size or number of cells positive for a particular marker, refers to a change of greater than about 5%. Thus, "increase," in the context of the size of multilayered cells or blastocyst-like structures, is understood to include an increase in size of at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 150%, at least 200%, at least 250%, at least 300% or more (compared to the size of the structures prior to culture in an in vitro attachment assay such as described herein). Similarly, an "increase" in the number of cells positive for a particular marker (such as NANOG and OCT4 / SOX2) can be an increase in the number of cells of at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 150%, at least 200%, at least 250%, at least 300% or more compared to the number of marker-positive cells in the construct before culturing in the in vitro attachment assay.
[0128] It will be appreciated that in the first aspect of the present invention, the multi-layered cell structure or blastocyst-like structure is obtained from a population of reprogrammed somatic cells (preferably reprogrammed human somatic cells) that exhibit epiblast (EPI), trophectoderm (TE) and primitive endoderm (PE) transcriptional signatures. The multi-layered cell structure or blastocyst-like structure may alternatively be produced by aggregation of iPSCs and iTSCs or populations of iPSCs and iTSCs. For example, a method for producing a multi-layered cell structure may comprise: - Culturing iPSC and iTSC cells under conditions that allow aggregation to obtain multi-layered cell structures. thereby creating a multi-layered cell structure.
[0129] Alternatively, there is a method for producing in vitro derived blastocyst-like structures, which method comprises: - Culturing iPSC and iTSC cells under conditions that allow aggregation to obtain blastocyst-like structures. thereby producing a blastocyst-like structure.
[0130] Methods for producing iPSCs and iTSCs are known in the art. Exemplary methods for producing iPSCs are described, for example, in Takahashi et al., (2007) Cell, 131:861-872, International Publication No. WO 2017 / 219232, International Publication No. WO 2014 / 200114, International Publication No. WO 2014 / 065435, International Publication No. WO 2019 / 073055, and Liu et al., (2017) Nat. Methods, 14:1055-1062 (the contents of which are all incorporated herein by reference in their entirety). Exemplary methods for producing iTSCs are described in Liu et al., (2020) Nature, 586:101-107 (the contents of which are also incorporated herein by reference).
[0131] In one embodiment, iPSCs and iTSCs can be co-cultured in any culture vessel described herein, e.g., a 24-well AggreWell™ 400 plate. Preferably, the cells are cultured in any culture medium (e.g., blastocyst-promoting medium or iBlastoid medium) that promotes the cells to exhibit at least one characteristic of a blastocyst-like structure as described herein. Preferably, the culture medium is iBlastoid medium as shown in Table 3a.
[0132] Preferably, iPSCs and iTSCs are cultured in the same well at a ratio of 1:2.5, respectively, at 1.2 x 10 per well. 5 The total number of cells to be co-cultured is:
[0133] In another aspect, the present invention also provides a multi-layered cell structure or a blastocyst-like structure produced by any of the methods as described herein.
[0134] Reprogramming Various methods are known in the art for reprogramming somatic cells toward a dedifferentiated or pluripotent state. Reprogramming of somatic cells typically involves the expression of reprogramming factors (including transcription factors) followed by culture under specific conditions to promote the loss of differentiation markers and the acquisition of pluripotency / plasticity markers.
[0135] According to the methods of the present invention, somatic cells are reprogrammed toward a dedifferentiated or pluripotent state before being subjected to culture conditions to promote the formation of multi-layered cell structures or blastocyst-like structures to obtain a population of cells exhibiting transcriptional signatures of the EPI, TE, or PE lineages. It will be appreciated that the population of cells thus comprises a reprogrammed intermediate upon being subjected to culture conditions to promote the formation of multi-layered cell structures or blastocyst-like structures. The reprogrammed intermediate exhibits transcriptional signatures of the EPI, TE, and / or PE lineages. Preferably, the population of intermediates exhibits transcriptional signatures for all three of the EPI, TE, and PE lineages.
[0136] The populations of reprogrammed intermediates produced according to the present invention can also be characterized by reference to the proportions of different cell populations that stain positively or negatively for the markers OCT4, GATA6 and CDX2, as shown in Figure 2h herein.
[0137] In any embodiment, the population of cells exhibiting a transcriptional signature of the EPI, TE, or PE lineage comprises a population of cells expressing at least one of the markers listed in Table 1 herein.
[0138] Preferably, the transcriptional signature of an EPI lineage comprises expression of at least 2, at least 3, at least 4, at least 5, at least 10, at least 15, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70 or more, or all, of the markers of an EPI lineage as listed in Table 1 herein. More preferably, the transcriptional signature of a TE lineage comprises expression of at least 2, at least 3, at least 4, at least 5, at least 10, at least 15, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70 or more, or all, of the markers of a TE lineage as listed in Table 1 herein. More preferably, the transcriptional signature of a PE lineage comprises expression of at least 2, at least 3, at least 4, at least 5, at least 10, at least 15, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70 or more, or all, of the markers of a PE lineage as listed in Table 1 herein.
[0139] In particularly preferred embodiments, the transcriptional signature of the EPI lineage comprises expression of any one, two, three, four, five, six, seven, eight, or nine or all of the following markers: ARGFX, NANOG, GDF3, SUSD2, DPPA5, POU5F1, UTF1, TDGF1, PDLIM1, and USP28; and the transcriptional signature of the TE lineage comprises expression of any one, two, three, four, five, six, seven, eight, or nine or all of the following markers: KRT18, KRT8, NODAL, UPP1, TAGLN2, KRT19, SL and the transcriptional signature of the PE lineage is expression of any one, two, three, four, five, six, seven, eight or nine or all of the markers: PALLD, FST, NOG, CLDN10, SERPINB6, MIAT, CHST2, VSNL1, MT1X, PDPN, SOX17 and GATA6.
[0140] Examples of suitable methods for reprogramming somatic cells are abundant in the art and are exemplified in WO 2009 / 101407, WO 2014 / 200030, WO 2015 / 056804, WO 2014 / 200114, WO 2014 / 065435, WO 2013 / 176233, WO 2012 / 060473, WO 2012 / 036299, WO 2011 / 158967, WO 2011 / 055851, WO 2011 / 037270, WO 2011 / 090221, the contents of which are incorporated herein by reference. Typically, such methods involve increasing the amount of one or more factors or agents in the starting cell type (or source cell) that have the ability (or are intended to) reprogram cells towards a pluripotent state.
[0141] In certain embodiments, the factor or agent for reprogramming a somatic cell or capable of reprogramming a somatic cell is a transcription factor. Alternatively, the factor or agent indirectly increases the level of one or more transcription factors in the cell, as further described herein. Particularly preferred transcription factors and their nucleic acid sequences that can be used to reprogram a somatic cell (e.g., a fibroblast) according to the methods of the present invention are set forth in Table 2. It will be understood that one or more, two or more, three or more, four or more, five or more, or all six of the transcription factors listed in Table 2 can be used in the present invention to reprogram a somatic cell. However, it will be understood that the present invention is not limited to using the transcription factors listed in Table 2 to reprogram a somatic cell.
[0142] Transcription factors and other protein factors referred to herein are referred to by HUGO Gene Nomenclature Committee (HGNC) symbols. Table 2 provides exemplary Ensembl gene IDs and Uniprot IDs for the transcription factors described herein. Nucleotide sequences are derived from the Ensembl database (Flicek et al. (2014). Nucleic Acids Research Volume 42, Issue D1. Pp. D749-D755) version 83. Any variants, homologs, orthologs, or paralogs of the transcription factors referred to herein are also contemplated for use in the present invention.
[0143] In certain embodiments, only a single cell type is subjected to reprogramming according to the methods of the present invention. In other words, preferably, the population of cells subjected to reprogramming is a homogeneous or substantially homogeneous cell population. For example, preferably, the population of cells comprises only or primarily fibroblasts or keratinocytes, or any other somatic cell type as described herein. Thus, it will be understood that only one starting cell type needs to be considered when determining the relevant factors suitable for reprogramming somatic cells toward a pluripotent state.
[0144] In other embodiments, a population of homogeneous cells (such as PBMCs) may be reprogrammed according to the methods described herein.
[0145] Those skilled in the art will recognize that this information may be used in practicing the methods of the invention, for example, to provide increased amounts of a transcription factor in somatic cells or to provide nucleic acids for recombinant expression of a transcription factor in somatic cells.
[0146] [Table 2]
[0147] The term "variant" refers to a polypeptide that is at least 70%, 80%, 85%, 90%, 95%, 98%, or 99% identical to the full-length polypeptide. The present invention contemplates the use of variants of the transcription factors described herein. Variants can be fragments of the full-length polypeptide or naturally occurring splice variants. Variants can be polypeptides that are at least 70%, 80%, 85%, 90%, 95%, 98%, or 99% identical to fragments of the polypeptide, where the fragments are at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, or 99%, so long as the full-length wild-type polypeptide or a domain thereof retains the desired functional activity, such as the ability to promote the conversion of one somatic cell type to a target cell type. In some embodiments, the domain is at least 100, 200, 300, or 400 amino acids in length, beginning at any amino acid position in the sequence and extending toward the C-terminus. Mutations known in the art that eliminate or substantially reduce the activity of a protein are preferably avoided. In some embodiments, variants lack N- and / or C-terminal portions of the full-length polypeptide, e.g., up to 10, 20, or 50 amino acids from either end. In some embodiments, the polypeptide has the sequence of a mature (full-length) polypeptide, by which we mean a polypeptide from which one or more portions, such as a signal peptide, have been removed during normal intracellular proteolytic processing (e.g., during co- or post-translational processing). In some embodiments, where the protein is produced by other than purifying it from cells that naturally express it, the protein is a chimeric polypeptide, meaning that it has portions from two or more different species. In some embodiments, where the protein is produced by other than purifying it from cells that naturally express it, the protein is a derivative, meaning that the protein contains additional sequences not related to the protein, so long as those sequences do not substantially reduce the biological activity of the protein.Those skilled in the art will know, or can easily ascertain using assays known in the art, whether a particular polypeptide variant, fragment, or derivative is functional. For example, the ability of a transcription factor variant to convert a somatic cell into a target cell type can be determined using assays as disclosed in the Examples herein. Another convenient assay involves measuring the ability to activate transcription of a reporter construct containing a transcription factor binding site operably linked to a nucleic acid sequence encoding a detectable marker, such as luciferase. In certain embodiments of the invention, a functional variant or fragment has at least 50%, 60%, 70%, 80%, 90%, 95%, or more of the activity of the full-length wild-type polypeptide.
[0148] With respect to increasing the amount of a factor for reprogramming cells toward a pluripotent state, the term "increasing the amount of" refers to increasing the amount of a factor (e.g., a transcription factor) in a cell of interest (e.g., a somatic cell such as a fibroblast). In some embodiments, the amount of a factor is "increased" when the amount of the factor in a cell of interest (e.g., a cell into which an expression cassette directing the expression of a polynucleotide encoding one or more factors has been introduced) is at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more, compared to a control (e.g., a fibroblast cell into which none of the expression cassettes has been introduced). However, any method of increasing the amount of a factor is contemplated, including any method that increases the amount, rate, or efficiency of transcription, translation, stability, or activity of the factor (or the pre-mRNA or mRNA encoding it). Additionally, downregulation or interference with negative regulators of transcriptional expression, or increasing the efficiency of existing translation (e.g., SINEUP) are also contemplated.
[0149] The term "agent," as used herein, refers to any compound or substance, including, but not limited to, a small molecule, nucleic acid, polypeptide, peptide, drug, ion, etc. An agent can be any compound or substance that increases the amount of a factor, including a transcription factor, as described herein. An "agent" can be any chemical entity or moiety, including, without limitation, synthetic and naturally occurring proteinaceous and non-proteinaceous entities. In some embodiments, an agent is a nucleic acid, nucleic acid analog, protein, antibody, peptide, aptamer, nucleic acid oligomer, amino acid, or carbohydrate, including, without limitation, a protein, oligonucleotide, ribozyme, DNAzyme, glycoprotein, siRNA, lipoprotein, aptamer, and modifications and combinations thereof. In certain embodiments, an agent is a small molecule having a chemical moiety. For example, the chemical moiety includes unsubstituted or substituted alkyl, aromatic, or heterocyclic moieties, including macrolides, leptomycins, and their related natural products or analogs. The compound can be known to have the desired activity and / or properties, or can be selected from a diverse library of compounds.
[0150] The term "exogenous," when used with reference to a protein, gene, nucleic acid, or polynucleotide of a cell or organism, refers to a protein, gene, nucleic acid, or polynucleotide that has been introduced into the cell or organism by artificial or natural means; or, when used with reference to a cell, refers to a cell that has been isolated and subsequently introduced into another cell or organism by artificial or natural means. An exogenous nucleic acid can be from a different organism or cell, or it can be one or more additional copies of a nucleic acid that naturally occurs within the organism or cell. An exogenous cell can be from a different organism, or it can be from the same organism. As a non-limiting example, an exogenous nucleic acid is one that is in a different chromosomal location than in the native cell, or is otherwise flanked by different nucleic acid sequences than those found in nature. An exogenous nucleic acid can also be extrachromosomal, such as an episomal vector.
[0151] Suitable detection means include the use of labels, such as radionucleotides, enzymes, coenzymes, fluorescers, chemiluminescers, chromogens, enzyme substrates or cofactors, enzyme inhibitors, prosthetic group complexes, free radicals, particles, dyes, and the like. Such labeled reagents may be used in a variety of well-known assays, such as radioimmunoassays, enzyme immunoassays, e.g., ELISAs, and fluorescence immunoassays. See, e.g., U.S. Patent Nos. 3,766,162; 3,791,932; 3,817,837; and 4,233,402.
[0152] The methods of the present disclosure can be "miniaturized" through any acceptable miniaturization method in assay systems, including but not limited to multiwell plates, microchips, or slides, such as 24, 48, 96, or 384 wells per plate. The assays can be reduced in size to be performed on microchip supports, which advantageously involve fewer amounts of reagents and other materials.
[0153] Culture vessel The formation of multi-layered cell structures or blastocyst-like structures is carried out in any suitable container, plate, system or vessel that allows for cell aggregation or self-organization. Typically, the culture is carried out in any culture plate, culture vessel, microfluidic system or culture system that allows for three-dimensional cell aggregation.
[0154] Suitable containers, plates, systems, or vessels preferably have a non-adherent surface. A non-adherent surface is a surface onto which cells are placed that has little or no tendency for cells to adhere. Thus, cells do not essentially adhere to the surface. Without wishing to be bound by theory, the use of a non-adherent surface provides a driving force for cells not to adhere to the surface, but instead to adhere to each other, thus forming cellular structures for use in the present invention.
[0155] The non-adhesive surface may be formed by coating the material with a non-adhesive biological or artificial material, or the non-adhesive surface may be obtained by imparting a suitable shape to a non-adhesive material or by other means known in the art. The container in or on which the cell aggregates may form will be referred to hereinafter as a scaffold.
[0156] Scaffolds with non-adhesive surfaces are made of or coated with, for example, ethylene oxide, propylene oxide, polyethylene glycol, (PEG)-(co)polymers (e.g., PLL-g-(PEG)), poly(ethylene oxide) (PEO) (co)polymers, agarose hydrogels, temperature-sensitive materials below their lower critical solution temperature (LCST) (e.g., poly(N-isopropylacrylamide)), hydrophobic materials (e.g., olefin polymers), cell-releasing micro- and nanotopographies.
[0157] Therefore, the formation of cell aggregates according to the present invention is preferably achieved using a non-adhesive scaffold. A non-adhesive scaffold has at least one surface that does not allow cell adhesion. Preferably, this is the side on which or within which the cells that will form the aggregates are placed. A non-adhesive scaffold can be formed of a non-adhesive material or can be formed of another material coated with a non-adhesive material. Although a non-adhesive Petri dish or a tube can be used as a scaffold, preferably, the scaffold has a plate-like shape, such as, for example, an approximately hexagonal, pentagonal, square, rectangular, triangular, oval, or circular shape.
[0158] More preferably, the scaffold contains at least one suitable cavity or channel. Preferably, the scaffold has multiple cavities or channels. It is preferable if the cavities or channels are somewhat larger than the size of the cell aggregates to be formed. Suitable cavities and channels are small, for example, 20-5000 μm in diameter, more preferably 100-1000 μm, and most preferably 100-500 μm in diameter, especially about 200 μm. Suitable cavities or channels can be obtained by any means known in the art. The diameter is defined as the longest possible linear distance between any two opposing points on the perimeter of the cavity or channel opening. The channel or cavity has a closed bottom, and at least the inner surface of the cavity or channel comprises a non-adhesive material.
[0159] Preferably, the cavity has a shape with approximately the same length and width. The depth is also approximately the same. Such a cavity is called a microwell. For the present invention, it is preferable if the non-adhesive scaffold includes a microwell. The microwell is preferably a cavity whose length is at most about 5 times, preferably 3 times, and more preferably approximately equal to, its width, and whose depth is no more than 10 times, preferably no more than 5 times, and more preferably no more than 3 times, its width.
[0160] The length of a microwell is defined as the longest possible linear distance between any two opposing points on the periphery of the opening of the microwell. The length of a microwell is therefore considered to be its diameter, which is preferably, for example, 20 to 5000 μm, more preferably 100 to 1000 μm, and most preferably 100 to 500 μm, and particularly about 200 μm. The width of a microwell is defined as the longest linear distance between any two opposing points on the periphery of the opening of the microwell perpendicular to its length.
[0161] The various cross-sectional areas of the microwells, particularly those perpendicular and parallel to the surface of the scaffold, can be any shape, including irregular, but preferably the possible cross-sectional areas of the microwells are independently square or nearly square, rectangular or nearly rectangular, triangular or nearly triangular, oval or nearly oval, or circular or nearly circular. However, it is preferred if the microwells are cylindrical and have circular openings on the approximately scaffold surface. Suitable microwells are present, for example, on microwell plates such as those commonly used in the art.
[0162] When the non-adhesive scaffold contains microwells, it is advantageous to have multiple microwells arranged in a single scaffold, preferably arranged in a regular pattern, which allows for high-throughput preparation of large numbers of blastoids.
[0163] In one embodiment, the culture vessel is a culture plate with an array of inverted pyramidal microwells of 400 μm or 800 μm, or about 400 μm to 800 μm, or approximately thereabouts. An exemplary culture plate is an AggreWell™ plate, such as the AggreWell™ 400 or 800. Within each well of an AggreWell plate are a number of microwells (e.g., each well of a 24-well Aggrewell has 1200 microwells).
[0164] Cells can be seeded or added to the microwells by adding a well-dispersed suspension of single cells of known density to the plate wells and gently centrifuging the plate to evenly press the cells into the microwells.
[0165] Conditions that allow for three-dimensional aggregation of cells include 0.5–2 × 10 cells per well. 5 Or about 0.5 to 2 × 10 5 Cells, 0.6–2 × 10 per well 5 or approximately 0.6 to 2 × 10 5 Cells, 0.8–2 × 10 per well 5or approximately 0.8 to 2 × 10 5 Cells, 1–2 × 10 per well 5 Or about 1 to 2 x 10 5 Cells, 0.6 x 10 per well 5 or about 0.6 x 10 5 Cells, 0.8 x 10 per well 5 or about 0.8 x 10 5 Cells, 1 x 10 per well 5 or about 1 x 10 5 Cells, 1.2 x 10 per well 5 or about 1.2 x 10 5 Cells, 1.4 x 10 per well 5 or about 1.4 x 10 5 Cells, 1.6 x 10 per well 5 or about 1.6 x 10 5 Cells, 1.8 x 10 per well 5 or about 1.8 x 10 5 2 x 10 cells per well 5 or about 2 x 10 5 This includes seeding the cells at a density (e.g., when seeding cells into an AggreWell plate as described herein; seeding can be 1-1000 cells per microwell). Preferably, the cells are in a single cell suspension prior to seeding. Preferably, the cells are reprogrammed somatic cells or cell populations of cells from step c) and / or step d) of the methods described herein that exhibit epiblast (EPI), trophectoderm (TE), and primitive endoderm (PE) transcriptional signatures.
[0166] Culture media and conditions The term "cell culture medium" (also referred to herein as "culture medium" or "culture medium"), as referred to herein, is a nutrient-containing medium for culturing cells that maintains cell viability and supports growth. Cell culture media may contain any of the following in appropriate combinations: one or more salts, one or more buffers, amino acids, glucose or other sugar(s), antibiotics, serum or serum replacements, and the like, components such as peptide growth factors, and the like. Cell culture media typically used for particular cell types are known to those of skill in the art. Exemplary cell culture media for use in the methods of the present invention are described herein, including those set forth in Table 3.
[0167] Somatic cells for use in the methods of the present invention do not need to be completely reprogrammed to a pluripotent state before contacting them with a culture medium in step c) as described herein. In other words, the cells are preferably in an intermediate state, transitioning from a differentiated state to a pluripotent state, at the time of contacting them with a culture medium that allows for aggregation to obtain blastocyst-like structures or multicellular structures. Thus, the cells at the end of step b) as described herein, before being cultured in step c), may be referred to as a reprogrammed intermediate.
[0168] In certain embodiments, the period of culture of cells to initiate reprogramming toward a pluripotent state is at least one day, beginning after the increase in protein expression or amount of one or more factors or when the cells are contacted with an agent to increase protein expression or amount of one or more factors. This period can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 days or more after the increase in protein expression or amount of one or more factors. In any embodiment, the period of culture of cells to initiate reprogramming toward a dedifferentiated pluripotent state can be any period of time, provided that it is possible to achieve a decrease in markers associated with somatic cells.
[0169] In further embodiments of the invention, the above methods comprise culturing cells toward a dedifferentiated or pluripotent state in a medium that induces upregulation of EPI, TE, and PE lineage transcriptional signatures. Preferably, the medium is one suitable for maintaining somatic cells (or source cells for reprogramming) in culture and is not a medium used to promote pluripotency or a medium used to promote pluripotency alone. When the somatic cells to be reprogrammed are fibroblasts, the medium is a fibroblast medium, e.g., a fibroblast medium as defined herein, including those in Table 3a and / or Table 3b. It will be appreciated that other media may be suitable, such as those in Table 3a and as shown in FIG. 11, or when the source cells for reprogramming are not fibroblasts (e.g., when the source cells are epithelial cells, endothelial cells, keratinocytes, etc.); examples of such media are also listed in Table 3b.
[0170] As used herein, the culture medium of step c) may also be referred to as blastocyst promoting medium or iBlastoid medium. Preferably, the blastocyst promoting medium or iBlastoid medium is as defined herein. In any embodiment, the cells in step c) are cultured in the culture medium for at least about 1, at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 8, at least about 10, at least about 12, at least about 14, at least about 16, at least about 20, at least about 24 days or more.
[0171] In any embodiment, the period between increasing the protein expression or amount of a factor for reprogramming somatic cells toward a pluripotent state and contacting the cells with culture medium in step c) can be any period that allows for a decrease in markers associated with the somatic cells. In a further example, the period between increasing the protein expression or amount of a factor and contacting the cells with culture medium in step c) can be any period that allows for the cells to progress through a mesenchymal-epithelial transition state. In further or alternative embodiments, this period can be any period that allows for the expression of epiblast (EPI), trophectoderm (TE), and primitive endoderm (PE) transcriptional signatures.
[0172] In another aspect, the present invention provides a culture medium for promoting cells to exhibit at least one characteristic of a blastocyst-like structure, comprising: - Agents that activate WNT pathway signaling (optionally GSK-3 inhibitors); - at least one, preferably two, TGF-β inhibitors, - HDAC inhibitors, growth factors (preferably EGF), and - BMP (preferably BMP4) A culture medium comprising:
[0173] In this embodiment, the agent that activates WNT pathway signaling (optionally a GSK-3 inhibitor), one or more TGF-β inhibitors, and HDAC inhibitor can be any one known in the art, including any one described herein.
[0174] Preferably, the culture medium comprises: - ITS-X; - L-glutamine; - N-acetyl-L-cysteine; - β-estradiol; - Progesterone; - 2-mercaptoethanol; - L-ascorbic acid; - transferrin (e.g., human), - insulin (e.g., human), - N2 supplement; and - B27 supplement Further includes:
[0175] Preferably, the progesterone, transferrin and insulin are provided in an N2 supplement further comprising putrescine and selenite as described herein.
[0176] Preferably, the B27 supplement includes biotin, DL-alpha tocopheryl acetate, DL-alpha tocopherol, vitamin A (acetate), BSA, catalase, insulin (human), superoxide dismutase, corticosterone, D-galactose, ethanolamine HCl, glutathione, L-carnitine HCl, linoleic acid, linolenic acid, progesterone, putrescine 2HCl, sodium selenite, T3 (triiodo-l-thyronine).
[0177] In any embodiment, the culture medium further comprises an antibiotic, such as penicillin-streptomycin.
[0178] In one embodiment, the culture medium comprises: - IVC1 medium, N2B27 basal medium and TSC basal medium as defined herein in a ratio of 2:1:1, respectively; - an agent for activating WNT pathway signaling (optionally a GSK-3 inhibitor), - at least one, preferably two, TGF-β inhibitors, - HDAC inhibitors, growth factors (preferably EGF), and - BMP (preferably BMP4) Includes:
[0179] Preferably, the TGF-β pathway inhibitor is selected from SB431542 and A83-01, the histone deacetylase (HDAC) 1 inhibitor is VPA (valproic acid), and the GSK-3 inhibitor is CHIR99021.
[0180] Preferably, the GSK-3 inhibitor is at a concentration of 2 μM or about 2 μM, the TGF-β pathway inhibitor is at a concentration of 0.5 μM or 1 μM or about 0.5 μM or 1 μM, the histone deacetylase (HDAC) 1 inhibitor is at a concentration of 0.8 mM or about 0.8 mM, EGF is at a concentration of 50 ng / ml or about 50 ng / ml, and BMP4 is at a concentration of 10 ng / ml or about 10 ng / ml.
[0181] As used herein, the term "growth factor" refers to any growth factor, preferably selected from epidermal growth factor (EGF), insulin, and transforming growth factor (TGF). The amount of growth factor may be any amount, for example, 0.1 to 1000 ng / ml, preferably 10 to 100 ng / ml, and preferably 50 ng / ml.
[0182] As used herein, a ROCK inhibitor refers to an inhibitor of Rho-associated kinase. Examples of such inhibitors include ((1R,4r)-4-((R)-1-aminoethyl)-N-(pyridin-4-yl)cyclohexanecarboxamide (Abcam), also known as trans-N-(4-(1-aminoethyl)-cyclohexanecarboxamide, 1-(5-isoquinolinyl)(sulfonyl)homopiperazine (1-(5-isoquinolinylsulfonyl)homopiperazine). Typically, the amount of ROCK inhibitor is about 0.1-50 μM, preferably about 1-10 μM.
[0183] Preferably, the ROCK inhibitor is Y-27632. Preferably, the ROCK inhibitor is at a concentration of 10 μM or about 10 μM.
[0184] In another embodiment, the culture medium comprises or consists of Fibroblast Medium, N2B27 Basal Medium, TSC Basal Medium, IVC1 Medium, IVC2 Medium or Human iBlastoid Medium as defined in Table 3a.
[0185] In any embodiment, the culture medium defined in step c) of any method of the invention can be any culture medium of the invention, including, but not limited to, human iBlastoid medium as defined herein, including those in Table 3a.
[0186] [Table 3a-1]
[0187] [Table 3a-2]
[0188] [Table 3a-3]
[0189] [Table 3b]
[0190] Nucleic acids and vectors A nucleic acid or a vector comprising a nucleic acid as described herein may include one or more of the sequences mentioned above in Table 2. The nucleic acid or vector may include a sequence encoding one or more of the factors for reprogramming a somatic cell towards a pluripotent state.
[0191] The term "expression" refers to the cellular processes involved in the production of RNA and proteins, and, where applicable, secretion of proteins, including but not limited to, transcription, translation, folding, modification and processing.
[0192] The terms "isolated" or "partially purified," as used herein, refer to a nucleic acid or polypeptide that has been separated from at least one other component (e.g., nucleic acid or polypeptide) that is present with the nucleic acid or polypeptide as found in its natural source and / or that would be present with the nucleic acid or polypeptide when expressed by a cell or secreted, in the case of a secreted polypeptide. Chemically synthesized nucleic acids or polypeptides or those synthesized using in vitro transcription / translation are considered "isolated."
[0193] The term "vector" refers to a carrier DNA molecule into which a DNA sequence can be inserted for introduction into a host or somatic cell. Preferred vectors are those capable of autonomous replication and / or expression of a nucleic acid to which it is linked. A vector capable of directing the expression of a gene to which it is operably linked is referred to herein as an "expression vector." Thus, an "expression vector" is a specialized vector that contains the necessary regulatory regions necessary for the expression of a gene of interest in a host cell. In some embodiments, the gene of interest is operably linked to another sequence within the vector. The vector can be a viral vector or a non-viral vector. When a viral vector is used, the viral vector is preferably replication-deficient, which can be achieved, for example, by removing all viral nucleic acid encoding replication. Replication-deficient viral vectors still retain their infectious properties and enter cells in a manner similar to replicating adenoviral vectors; however, after entering the cell, replication-deficient viral vectors do not replicate or propagate. Vectors also include liposomes and nanoparticles, as well as other means of delivering DNA molecules to cells.
[0194] The term "operably linked" means that regulatory sequences required for expression of a coding sequence are positioned relative to the coding sequence within the DNA molecule so as to effect expression of the coding sequence. This same definition is sometimes applied to the arrangement of coding sequences and transcription control elements (e.g., promoters, enhancers, and termination elements) within an expression vector. The term "operably linked" includes having an appropriate initiation signal (e.g., ATG) in front of the polynucleotide sequence to be expressed, and maintaining the correct reading frame to permit expression of the polynucleotide sequence under the control of the expression control sequences and production of the desired polypeptide encoded by the polynucleotide sequence.
[0195] The term "viral vector" refers to the use of a virus or virus-associated vector as a carrier of a nucleic acid construct into a cell. The construct can be incorporated into and packaged in a non-replicating defective viral genome, such as adenovirus, adeno-associated virus (AAV), or herpes simplex virus (HSV), or other retroviral and lentiviral vectors, including Sendai virus vectors, for infecting or transducing cells. The vector may or may not be integrated into the cellular genome. The construct can optionally include viral sequences for transfection. Alternatively, the construct can be incorporated into a vector capable of episomal replication, such as EPV and EBV vectors.
[0196] As used herein, the term "adenovirus" refers to viruses of the Adenoviridae family. Adenoviruses are medium-sized (90-100 nm), non-enveloped (naked), icosahedral viruses composed of a nucleocapsid and a double-stranded linear DNA genome.
[0197] As used herein, the term "non-integrating viral vector" refers to a viral vector that does not integrate into the host genome; expression of genes delivered by this viral vector is transient. Because there is little to no integration into the host genome, non-integrating viral vectors have the advantage of not causing DNA mutations by insertion at random points in the genome. For example, non-integrating viral vectors remain extrachromosomal and do not insert their genes into the host genome, so they do not have the potential to disrupt endogenous gene expression. Non-integrating viral vectors include, but are not limited to, adenoviruses, alphaviruses, picornaviruses, and vaccinia viruses. Although it is possible that any of these may, in some rare circumstances, integrate viral nucleic acid into the genome of a host cell, these viral vectors are "non-integrating" viral vectors as this term is used herein. Crucially, the viral vectors used in the methods described herein do not integrate their nucleic acid into the genome of a host cell, either as a rule or as a major part of their life cycle under the conditions used.
[0198] The vectors described herein can be constructed and engineered using methods generally known in the scientific literature to increase their safety when used in therapeutics, to include selection and enrichment markers as needed, and to optimize expression of the nucleotide sequences contained therein. The vector must contain structural components that allow the vector to self-replicate in its somatic cell type. For example, the known Epstein-Barr oriP / nuclear antigen-1 (EBNA-I) combination (see, e.g., Lindner, S.E. and B. Sugden, "The plasmid replicon of Epstein-Barr virus: mechanistic insights into efficient, licensed, extrachromosomal replication in human cells," Plasmid 58:1 (2007) (incorporated by reference in its entirety)) is sufficient to support vector self-replication; other combinations known to function in mammalian, particularly primate, cells can also be used. Standard techniques for constructing expression vectors suitable for use in the present invention are well known to those skilled in the art, and reference may be made to publications such as Sambrook J, et al., "Molecular cloning: a laboratory manual," (3rd ed. Cold Spring Harbor Press, Cold Spring Harbor, NY 2001) (incorporated herein by reference as if set forth in its entirety).
[0199] In the methods of the invention, genetic material encoding the relevant transcription factors required for conversion is delivered to the somatic cell by one or more reprogramming vectors. Each transcription factor can be introduced into the somatic cell as a polynucleotide transgene encoding the transcription factor operably linked to a heterologous promoter capable of driving expression of the polynucleotide in the somatic cell.
[0200] Suitable reprogramming vectors include any of those described herein that do not encode all or part of a viral genome sufficient to produce an infectious or replication-competent virus, including episomal vectors such as plasmids, although such vectors can contain structural elements obtained from more than one virus. One or more reprogramming vectors can be introduced into a single somatic cell. One or more transgenes can be provided in a single reprogramming vector. A single strong constitutive transcription promoter can provide transcriptional control for multiple transgenes, which can be provided as expression cassettes. Separate expression cassettes on a vector can be under the transcriptional control of separate strong constitutive promoters, which can be copies of the same promoter or different promoters. A variety of heterologous promoters are known in the art and can be used depending on factors such as the desired expression level of transcription factors. As exemplified below, it can be advantageous to control the transcription of separate expression cassettes in a cell using different promoters with different strengths. Another consideration in selecting a transcription promoter is the rate at which one or more promoters are silenced. Those skilled in the art will recognize that it may be advantageous to reduce the expression of one or more transgenes or transgene expression cassettes after the production of one or more genes is complete or after their role in the reprogramming method has been substantially completed. Exemplary promoters include the human EF1α elongation factor promoter, the CMV cytomegalovirus immediate-early promoter, and the CAG chicken albumin promoter, as well as corresponding homologous promoters from other species. In human somatic cells, both EF1α and CMV are strong promoters, but the CMV promoter is silenced more efficiently than the EF1α promoter, so that expression of transgenes under the former control is turned off more quickly than transgenes under the latter control. By expressing these transcription factors in somatic cells in varying relative ratios, reprogramming efficiency can be adjusted.Preferably, when multiple transgenes are encoded on a single transcript, an internal ribosome entry site is provided upstream of one or more of the transgenes, distal to the transcriptional promoter. The relative ratios of factors may vary depending on the factors being delivered, but the skilled artisan armed with this disclosure will be able to determine the optimal ratio of factors.
[0201] Those skilled in the art will recognize that the efficiency of introducing all factors is favored by using a single vector rather than multiple vectors, but that as the overall vector size increases, vector introduction becomes increasingly difficult. Those skilled in the art will also recognize that the location of a transcription factor on a vector can affect its temporal expression and the resulting reprogramming efficiency. Thus, the methods of the present invention can be practiced using various combinations of factors in combination with vectors. Some such combinations are known to support reprogramming.
[0202] After introducing one or more reprogramming vectors, the vectors can remain in the target cells while the somatic cells are being reprogrammed, while the introduced transgenes are transcribed and translated.Transgene expression can be advantageously downregulated or turned off in cells that have been reprogrammed into the target cell type.One or more reprogramming vectors remain extrachromosomal.When the efficiency is extremely low, one or more vectors can be integrated into the cell's genome.The following examples are intended to illustrate the present invention, but are not intended to limit the present invention in any way.
[0203] Nucleic acid delivery methods suitable for transforming cells, tissues, or organisms for use in the present invention are intended to include virtually any method capable of introducing nucleic acid (e.g., DNA) into cells, tissues, or organisms, as described herein or as would be known to one of skill in the art (e.g., Stadtfeld and Hochedlinger, Nature Methods 6(5):329-330 (2009); Yusa et al., Nat. Methods 6:363-369 (2009); Woltjen, et al., Nature 458,766-770 (9 Apr. 2009)). Such methods include, but are not limited to, direct delivery of DNA, e.g., ex vivo transfection (Wilson et al., Science, 244:1344-1346, 1989; Nabel and Baltimore, Nature 326:711-713, 1987), optionally with lipid-based transfection reagents such as Fugene6 (Roche) or Lipofectamine (Invitrogen), injection (U.S. Pat. Nos. 5,994,624, 5,981,274, 5,945,100, 5,780,448, 5,736,524, 5,702,932, 5,656,610, 5,589,466, and 5,580,859, each of which is incorporated herein by reference), microinjection (Harland and Weintraub, J. Cell 2004, 10, 110-120). Biol., 101:1094-1099, 1985; U.S. Pat. No. 5,789,215, incorporated herein by reference); by electroporation (U.S. Pat. No. 5,384,253, incorporated herein by reference; Tur-Kaspa et al., Mol. Cell Biol., 6:716-718, 1986; Potter et al., Proc. Nat'l Acad. Sci.USA, 81:7161-7165, 1984); by calcium phosphate precipitation (Graham and Van Der Eb, Virology, 52:456-467, 1973; Chen and Okayama, Mol. Cell Biol., 7(8):2745-2752, 1987; Rippe et al., Mol. Cell Biol., 10:689-695, 1990); by using DEAE-dextran followed by polyethylene glycol (Gopal, Mol. Cell Biol., 5:1188-1190, 1985); by direct sonication (Fechheimer et al., Proc. Nat'l Acad. Sci. USA, 84:8463-8467, 1987); by liposome-mediated transfection (Nicolau and Sene, Biochim. Biophys. Acta, 721:185-190, 1982; Fraley et al., Proc. Nat'l Acad. Sci. USA, 76:3348-3352, 1979; Nicolau et al., Methods Enzymol., 149:157-176, 1987; Wong et al., Gene, 10:87-94, 1980; Kaneda et al., Science, 243:375-378, 1989; Kato et al., J. Biol. Chem., 266:3361-3364, 1991) and receptor-mediated transfection (Wu and Wu, Biochemistry, 27:887-892, 1988; Wu and Wu, J. Biol. Chem., 262:4429-4432, 1987); and any combination of such methods (each of which is incorporated herein by reference).
[0204] A number of polypeptides capable of mediating the delivery of relevant molecules into cells have been described and can be applied to the present invention, see, for example, Langel (2002) Cell Penetrating Peptides: Processes and Applications, CRC Press, Pharmacology and Toxicology Series. Examples of polypeptide sequences that enhance transport across membranes include, but are not limited to, the Drosophila homeoprotein Antennapedia transcription protein (AntHD) (Joliot et al., New Biol. 3:1121-34, 1991; Joliot et al., Proc. Natl. Acad. Sci. USA, 88:1864-8, 1991; Le Roux et al., Proc. Natl. Acad. Sci. USA, 90:9120-4, 1993), herpes simplex virus structural protein VP22 (Elliott and O'Hare, Cell 88:223-33, 1997); the HIV-1 transcriptional activator TAT protein (Green and Loewenstein, Cell 55:1179-1188, 1988; Frankel and Pabo, Cell 55:1 289-1193, 1988); Kaposi's FGF signal sequence (kFGF); protein transduction domain-4 (PTD4); penetratin, M918, transportan-10; nuclear localization sequences, PEP-I peptide; amphipathic peptides (e.g., MPG peptide); delivery-enhancing transporters such as those described in U.S. Pat. No. 6,730,293 (including, but not limited to, peptide sequences containing at least 5-25 or more consecutive arginines or 5-25 or more arginines in a consecutive set of 30, 40, or 50 amino acids; including, but not limited to, peptides having sufficient, e.g., at least 5 guanidino or amidino moieties); and the commercially available Penetratin™ 1 peptide and Diatos Peptide Vector ("DPV") from the Vectocell® platform available from Daitos SA, Paris, France.See also WO 2005 / 084158 and WO 2007 / 123667 and the further transporters described therein. Not only are these proteins able to cross cell membranes, but the attachment of other proteins, such as the transcription factors described herein, is sufficient to stimulate cellular uptake of these complexes.
[0205] Uses and Applications The multi-layered cell structures or blastocyst-like structures as produced according to the present invention may also be used to prepare model systems for disorders related to the development and / or activity of blastocysts or the cells therein, which systems find utility in screening for genes expressed in or essential for blastocyst differentiation and / or activity, screening for drugs and conditions (such as culture conditions and manipulations) that affect development, producing certain growth factors and hormones, or as cell therapy for development-related disorders.
[0206] Thus, according to one aspect of the present invention there is provided a method for identifying an agent capable of modulating blastocyst development and / or activity, comprising the steps of: (i) contacting a multi-layered cell structure or a blastocyst-like structure, preferably produced according to the methods of the present invention, with a candidate drug; and (ii) comparing the development and / or activity of the multi-layered cell structure or blastocyst-like structure after said contact with said agent with the development and / or activity of the multi-layered cell structure or blastocyst-like structure without the agent. wherein the effect of the drug on said development and / or activity of the multi-layered cell structure or blastocyst-like structure is greater than the development and / or activity of the multi-layered cell structure or blastocyst-like structure in the absence of the drug by a predetermined level, indicating that the drug modulates the development and / or activity of the blastocyst.
[0207] As used herein, the term "modulating" refers to altering the development and / or activity of the blastocyst by either inhibiting or promoting it.
[0208] According to a specific embodiment, modulating is inhibiting development and / or activity.
[0209] According to a specific embodiment, modulating is promoting development and / or activity.
[0210] For the same culture conditions, the effect of a candidate drug on the development and / or activity of multi-layered cell structures or blastocyst-like structures is generally expressed in comparison with the development and / or activity in multi-layered cell structures or blastocyst-like structures of the same species but not contacted with the candidate drug or contacted with a vehicle control, also referred to as the control.
[0211] As used herein, the phrase "effect greater than a predetermined level" refers to a change in the development and / or activity of the multi-layered cell structure or blastocyst-like structure after contact with an agent that is greater than a predetermined level, such as about 10%, for example, about 20% greater, for example, about 30% greater, for example, about 40% greater, for example, about 50% greater, for example, about 60% greater, about 70% greater, about 80% greater, about 90% greater, about 2-fold greater, about 3-fold greater, about 4-fold greater, about 5-fold greater, about 6-fold greater, about 7-fold greater, about 8-fold greater, about 9-fold greater, about 20-fold greater, about 50-fold greater, about 100-fold greater, about 200-fold greater, about 350-fold greater, about 500-fold greater, about 1000-fold greater or more, compared to the presence or level of any marker described herein before contact with the candidate agent.
[0212] According to specific embodiments, the candidate agent may be any compound, including but not limited to, chemical compounds, small molecules, polypeptides, and polynucleotides.
[0213] According to specific embodiments, the selected agent may further be used to treat a variety of conditions requiring modulation of blastocyst development or activity, such as those conditions described herein.
[0214] According to another aspect of the present invention, since blastocysts produce several secreted growth factors and hormones as well as particles such as exosomes, there is provided a method for obtaining compounds or particles produced by multi-layered cell structures or blastocyst-like structures, which comprises culturing the multi-layered cell structures or blastocyst-like structures of the present invention and isolating the compounds or particles secreted by the cells from the culture medium, thereby obtaining compounds or particles produced by the multi-layered cell structures or blastocyst-like structures.
[0215] As outlined herein, the present invention provides a method for directly reprogramming somatic cells into human blastoids and does not involve the use of naturally occurring human blastocysts. - without destruction of the embryo; - without fertilization; - without oocyte activation; - unable to develop into a human; and - is not a step in the process of creating a human; and - Without primary natural media taken from pregnant women.
[0216] Furthermore, the culture of the multilayered cell structures or blastocyst-like structures should be for the minimum amount of time necessary, e.g., a maximum of 5 additional days (corresponding to approximately E11), preferably 4.5 days, and the experiment should be terminated before morphological evidence of a primitive streak. [Example]
[0217] Example 1 - Ethics Statement This study was approved by the Institutional Monash University Human Research Ethics Committee (MUHREC 2020-22909-39935 and MUHREC 2020-27147-51995). MUHREC 2020-22909-39935 covered the functional and molecular characterization of human fibroblasts undergoing reprogramming using a 3D organoid-based culture system (blastoids). MUHREC 2020-27147-51995 covered the generation, molecular, and functional characterization of iBlastoids.
[0218] Furthermore, because there is currently no precedent for working with a human blastoid model, while seeking approval from our institutional human research ethics committee, we conducted all experiments in accordance with published recommendations (Hyun et al. Stem Cell Reports 14, 169-174 (2020)) and in compliance with the international agreement limiting human embryo culture to 14 days post-fertilization and / or the formation of the primitive streak (PS), whichever occurs first (Warnock, Ir. Nurs. News 5, 7-8 (1985)).
[0219] Given the uncertainty regarding the applicability of the "14-day rule" for iBlastoids (due to the non-embryonic origin of the starting material), HDFs are derived from adult tissue, we focused on culturing iBlastoids for the minimum amount of time necessary, in this case a maximum of 5 additional days (corresponding to approximately E11), and terminating the experiment before morphological evidence of PS, to remain well within international guidelines (Hyun and Warnock, supra).
[0220] To exclude molecular evidence of PS formation, we performed a qRT-PCR 24-hour time course analysis of several key primitive streak markers during 5-day embryo attachment culture (Xiang, L. et al. Nature 577, 537-542 (2020); Takahashi, K. et al. Nat. Commun. 5, 3678 (2014); Tyser, et al. bioRxiv (2020)) and did not observe upregulation of TBXT, Eomes, or MIXL1 or any morphological changes indicative of gastrulation (Tyser, supra; O'Rahilly, R. & Mueller, F. Developmental stages in human embryos: revised and new measurements. Cells Tissues Organs 192, 73-84 (2010); Yamaguchi, Y. & Yamada, S. Cells Tissues Organs 205, 314-319 (2018)) (Figure 8b, Figure 8a). Thus, the 5-day iBlastoid adherent culture did not result in the formation of the EPI compartment. Nevertheless, by strictly adhering to the above parameters, all subsequent human iBlastoid adherent culture experiments were performed for a total of 4.5 days after iBlastoid formation (Figure 8a).
[0221] Example 2 - Cell Culture Medium Fibroblast medium: DMEM (ThermoFisher), 10% fetal bovine serum (FBS, ThermoFisher), 1% non-essential amino acids (ThermoFisher), 1 mM GlutaMAX (ThermoFisher), 1% penicillin-streptomycin (ThermoFisher), 55 μM 2-mercaptoethanol (ThermoFisher), and 1 mM sodium pyruvate (ThermoFisher).
[0222] N2B27 basal medium: a 50:50 mixture of DMEM / F-12 (ThermoFisher) and Neurobasal medium (ThermoFisher) supplemented with 2 mM L-glutamine (ThermoFisher), 0.1 mM 2-mercaptoethanol (ThermoFisher), 0.5% N2 supplement (ThermoFisher), 1% B27 supplement (ThermoFisher), and 1% penicillin-streptomycin (ThermoFisher).
[0223] TSC basal medium: DMEM / F-12, GlutaMAX (ThermoFisher), supplemented with 0.3% BSA (Sigma), 0.2% FBS (ThermoFisher), 1% ITS-X supplement (ThermoFisher), 0.1 mM 2-mercaptoethanol (ThermoFisher), 0.5% penicillin-streptomycin (ThermoFisher), and 1.5 μg / ml L-ascorbic acid (Sigma).
[0224] IVC1 medium: Advanced DMEM / F-12 (ThermoFisher), 1% ITS-X supplement (ThermoFisher), 2 mM L-glutamine (ThermoFisher), 0.5% penicillin-streptomycin (ThermoFisher), 20% fetal bovine serum (FBS, ThermoFisher), 25 μM N-acetyl-L-cysteine (Sigma), 8 nM β-estradiol (Sigma), and 200 ng / ml progesterone (Sigma). IVC2 medium: Advanced DMEM / F-12 (ThermoFisher), 1% ITS-X supplement (ThermoFisher), 2 mM L-glutamine (ThermoFisher), 0.5% penicillin-streptomycin (ThermoFisher), 30% knockout serum replacement (KSR, ThermoFisher), 25 μM N-acetyl-L-cysteine (Sigma), 8 nM β-estradiol (Sigma), and 200 ng / ml progesterone (Sigma).
[0225] Human iBlastoid medium: IVC1 medium, N2B27 basal medium and TSC basal medium in a 2:1:1 ratio, respectively, supplemented with 2 μM CHIR99021 (Miltenyi Biotec), 0.5 μM A83-01 (Sigma), 1 μM SB431542, 0.8 mM valproic acid (VPA, Sigma), 50 ng / ml EGF (Peprotech) and 10 ng / ml BMP4 (Miltenyi Biotec).
[0226] TIFF2023550181000007.tif193161
[0227] Example 3 - Creating iBlastoids by Reprogramming All cell lines used in this study were authenticated and mycoplasma tested as described in the Reporting Summary. Primary human adult dermal fibroblasts (HDFa) from three different female donors were obtained from ThermoFisher (catalog no. C-013-5C and lot no. 1029000 for 38F, lot no. 1528526 for 55F, and lot no. 1569390 for 32F). Cells were recovered and expanded in Medium 106 (ThermoFisher) supplemented with low serum growth supplement (LSGS) (ThermoFisher).
[0228] Human somatic cell reprogramming was performed as previously described (Liu, X. et al. Nat. Methods 14, 1055-1062 (2017)) to obtain day 21 reprogrammed intermediates. Briefly, human fibroblast reprogramming was performed using the CytoTune-iPS 2.0 Sendai Reprogramming Kit (ThermoFisher, Lot No. 2170052) according to the manufacturer's instructions. Primary HDFa cells were cultured in fibroblast medium at approximately 5–10 × 10 4Cells were seeded at a density of 1.2 × 10 cells per well in 24-well Aggrewell plates (Stem Cell Technologies) in human iBlastoid medium supplemented with 10 μM Y-27632 (ROCK inhibitor, Selleckchem) according to the manufacturer's instructions. Cells were transduced with Sendai virus in FM at the following multiplicity of infection (MOI): KOS (KLF4-OCT4-SOX2) MOI = 5, c-MYC MOI = 5, and KLF4 MOI = 6, as shown in Figure 1a. Medium changes were performed every other day starting on day 1 post-transduction and daily from day 8 onwards. On day 21 of reprogramming, cells were dissociated and plated at 1.2 × 10 cells per well in human iBlastoid medium supplemented with 10 μM Y-27632 (ROCK inhibitor, Selleckchem) according to the manufacturer's instructions. 5 Cells were seeded at a density of 1000 x g / ml. Cells were cultured in an incubator at 37°C, 5% O2, and 5% CO2. After 24 hours, cells were replenished with fresh human iBlastoid medium without ROCK inhibitor. On day 6 of iBlastoid formation in Aggrewell, iBlastoids were harvested for subsequent analysis or in vitro adhesion assays. Details of the culture medium used to generate iBlastoids are summarized in Example 2 above.
[0229] We performed somatic cell reprogramming as previously described (Liu, X. et al. Nat. Methods 14, 1055-1062 (2017)), using integration-free Sendai virus to deliver OCT4 / POU5F1, KLF4, SOX2, and c-MYC (OKSM) transcription factors (TFs) to obtain day 21 reprogrammed intermediates. Alternatively, we performed somatic cell reprogramming by mRNA transfection of the transcription factors, as further described in Example 11 herein. We also demonstrated that similar techniques can be used to reprogram other somatic cells, as described in Examples 12 and 13, thus establishing that reprogrammed intermediates can be obtained from a variety of somatic cells for use in the methods of the present invention.
[0230] When the intermediates were switched to the AggreWell system with a medium containing a WNT activator, a TGF-β inhibitor, an HDAC inhibitor, EGF, and BMP4 (see Methods) (Fig. 1a), the intermediates began to form aggregates, forming cavities on day 3 and gradually expanding (Fig. 2b). By day 5–6, blastocyst-like structures became evident (Fig. 1b). Immunofluorescent staining of these structures for NANOG revealed an inner cell mass (ICM)-like intracellular compartment containing NANOG-positive cells, surrounded by an outer layer of NANOG-negative cells, along with a blastocoel-like cavity (Fig. 1c). Because these structures were obtained directly by somatic cell reprogramming, we termed them "human-derived blastoids" (iBlastoids). Furthermore, measurements of the iBlastoid's x- and y-axis diameters, x:y aspect ratio, and projected area revealed that it was comparable in size to previously published measurements of human blastocysts at embryonic day 5–7 (E5–E7) (Figures 1d–h). Additionally, the cell counts of iBlastoids ranged from 100–400, with a median of approximately 280 cells. While the median cell count is slightly higher than reported values for E5–E7 human blastocysts (approximately 240 cells), it is still within the range previously reported for E5–E7 blastocysts (Figure 1i). To quantify the iBlastoid formation efficiency, we counted 100 random structures and found that 14% exhibited typical blastocyst-like morphology, including a blastocoel cavity (Figure 2c). During iBlastoid formation in the AggreWell system, adherent cell clusters that were not part of the iBlastoid were consistently observed along the edges of the microwells. These were hypothesized to be refractory fibroblasts from the reprogrammed cultures (Figure 2d). To confirm this, we isolated these cell clusters and cultured them in fibroblast medium, resulting in the proliferation of cells with classical fibroblast morphology (Figure 2d). This suggested that these reprogrammed refractory fibroblasts did not contribute to iBlastoid formation.Scoring of iBlastoids according to the method described in The Istanbul consensus workshop on embryo assessment: proceedings of an expert meeting. Hum. Reprod. 26, 1270-1283 (2011) using IVF blastocyst quality criteria (good = 1, fair = 2, or poor = 3) showed that iBlastoids were given good or fair scores, with average scores of 1.75 for ICM and 1.67 for TE (Figures 2i-k).
[0231] In summary, these data demonstrate that reprogramming intermediates can be used to directly generate human blastocyst-like structures, termed "iBlastoids," that are structurally similar to blastocysts.
[0232] Example 4 - Materials and Methods for iBlastoid Characterization Immunofluorescence staining iBlastoids / cells were fixed in 4% paraformaldehyde (PFA, Sigma), permeabilized with 0.5% Triton X-100 (Sigma) in DPBS (ThermoFisher), and blocked with blocking buffer (3% bovine serum albumin (BSA) (Sigma) + 0.1% Tween-20 (Sigma) in DPBS (ThermoFisher)). All antibodies used in this study are listed in the table below.
[0233] TIFF2023550181000008.tif217161
[0234] TIFF2023550181000009.tif41161
[0235] For example, the primary antibodies used were rabbit anti-NANOG polyclonal antibody (1:100, Abcam) and mouse anti-CDX2 IgG1 (1:50, Abcam) prepared in blocking buffer. Primary antibody incubation was performed overnight at 4°C on a shaker, followed by a 3-hour incubation with the secondary antibody (1:500 in blocking buffer). The secondary antibodies used in this study were goat anti-rabbit IgG AF555 (1:500, ThermoFisher) or goat anti-rabbit IgG AF647 (1:500, Invitrogen) for NANOG, and goat anti-mouse IgG AF488 (1:400, ThermoFisher) or goat anti-mouse IgG AF488 (1:500, ThermoFisher) for CDX2. After labeling, iBlastoids / cells were stained with 4',6-diamidino-2-phenylindole, dihydrochloride (DAPI, ThermoFisher) at a concentration of 5 μg / ml in blocking buffer for 1 hour. Images were acquired using an SP8 inverted confocal microscope (Leica) or an LSM780 multiphoton confocal microscope (Zeiss).
[0236] Confocal imaging and analysis Immunostained iBlastoids were imaged using an SP8 inverted confocal microscope (Leica) or a laser scanning confocal microscope (LSM 780 microscope, Zeiss) with a Confocor 3 module (Zeiss) water immersion UV-Vis-IR apochromatic 40x 1.2NA objective and a highly sensitive avalanche photodiode photodetector. Three-dimensional visualization of iBlastoids was performed using Imaris 9.5 software (Bitplane AG). A manual surface rendering module was used for cell and iBlastoid segmentation. Final images were processed and assembled using Adobe Photoshop or ImageJ.
[0237] Fluorescence-activated cell sorting (FACS) iBlastoids were dissociated with TrypLE Express (ThermoFisher), and samples were finally resuspended using DPBS (ThermoFisher) supplemented with 2% FBS (ThermoFisher) and 10 μM Y-27632 (Selleckchem). Dissociated cells were pelleted at 400 × g for 5 min and then resuspended in a final volume of 500 μl with propidium iodide (PI) (Sigma) at a concentration of 2 μg / ml. Cell sorting was performed using a 100 μm nozzle on an Influx instrument (BD Biosciences).
[0238] Quantitative RT-PCR RNA was extracted from cells using the RNeasy Micro Kit (Qiagen) or RNeasy Mini Kit (Qiagen) and QIAcube (Qiagen) according to the manufacturer's instructions. Reverse transcription was then performed using the SuperScript III cDNA Synthesis Kit (ThermoFisher) or QuantiTect Reverse Transcription Kit (Qiagen, catalog no. 205311). Real-time PCR reactions were set up in triplicate using the QuantiFast SYBR Green PCR Kit (Qiagen) and then run on a 7500 Real-Time PCR System (ThermoFisher). The qRT-PCR primers used in this study are listed in the table below.
[0239] TIFF2023550181000010.tif94161
[0240] Mesoderm differentiation Positive controls for qRT-PCR of primitive streak markers were obtained by modifying a previously published mesoderm differentiation protocol (Lam, AQ et al. J. Am. Soc. Nephrol. 25, 1211–1225 (2014)). Briefly, human iPSCs grown to 50% confluency in E8 medium (ThermoFisher) were cultured in RPMI, GlutaMAX (ThermoFisher), 1% B27 supplement (ThermoFisher), 1% penicillin-streptomycin (ThermoFisher), and 5 μM CHIR99021 (Miltenyi Biotec). After 48 h, differentiated cells were harvested for qRT-PCR analysis, revealing high expression of the primitive streak markers TBXT, Eomes, and MIXL1 (Figure 8b).
[0241] hCG ELISA iBlastoid generation and in vitro adhesion assays were performed as described in the "In Vitro Adhesion Assay" example below. Media was collected for both iBlastoids (day 6) and adhered iBlastoids (day 6 + 4.5) and stored at -80°C. hCG levels in the media were measured using an hCG ELISA kit (Abnova, ABNOKA4005) according to the manufacturer's instructions.
[0242] iBlastoid Single-Cell RNA Sequencing (scRNA-seq) For scRNA-seq experiments, iBlastoids were dissociated as described in the previous section to obtain single-cell suspensions for FACS. Cells were then sorted for scRNA-seq by FACS to obtain PI-negative, debris-free, single viable cells. The harvested cells were isolated, packaged, and assembled using a Chromium controller (10x Genomics) according to the manufacturer's instructions, "Chromium Next GEM Single Cell 3' Reagent Kit V3.3 User Guide." Sequencing was performed on an Illumina NovaSeq 6000 using a paired-end (R1 28 bp and R2 87 bp) sequencing strategy with a target of 20,000 read pairs per cell. Demultiplexing was performed using Chromium barcodes, and FASTQ files were generated from the mkfastq pipeline using the Cellranger program (v3.1.0, http: / / software.10xgenomics.com / single-cell / overview / welcome). Alignment and UMI counting were performed using Cellranger, which utilizes the STAR aligner (Dobin, A. et al. Bioinformatics 29, 15-21 (2013)) to map sequencing reads to a custom version of the Ensembl GRCh37.87 reference genome, which we extended with sequences from custom Sendai KLF4, MYC, and SEV (KOS) vectors. This step resulted in 9060 unique cell barcodes.
[0243] iBlastoid scRNA-seq cell donor identification To determine the identity of individual donors for each cell, we used the Bayesian demultiplexing tool Vireo (v0.3.2) (Huang, Genome Biol. 20, 273 (2019)). Briefly, we used cellSNP (v0.3.0) to compile expressed alleles in the single-cell data and generate a list of single-nucleotide polymorphisms (SNPs) with a minimum allele frequency (using the argument minMAF) of 0.1 and a minimum unique molecular identifier (using the argument minCOUNT) of 20. Furthermore, cellSNP requires a reference list of human variants to call SNPs. We used a precompiled SNP list from the 1000 Genomes Project provided by the Vireo authors (downloaded from https: / / sourceforge.net / projects / cellsnp / files / SNPlist / ). Specifically, we used a list of hg19 genome-based variants with a minor allele frequency >0.05, containing 7.4 million SNPs. Vireo was then performed to demultiplex the single-cell library by separating the cells into two donor populations. Note that Vireo can only distinguish cells with respect to these two donors, but cannot assign the donor identity itself (32F or 38F) to each cell.
[0244] iBlastoid scRNA-seq cell calling and quality control First, cell-level quality control was performed. Cells with (i) both or neither evidence of cell line donor, (ii) a low number of expressed genes [nGene], or (iii) a high proportion of mitochondrial genes [pctMT] were discarded. A cutoff of nGene < 1,300 pctMT > 15 was applied to discard cells. Next, gene-level quality control was performed. Genes were filtered if they were absent from at least 50 cells with at least one read each. All cutoffs were determined after examining the distribution of each variable. After quality control, 6,858 cells and 14,224 genes remained for scRNA-seq.
[0245] iBlastoid scRNA-seq analysis Analyses in the remainder of this section were performed using R (v3.6)55 with Seurat (v3.1.5) (Butler, et al. Nat. Biotechnol. 36, 411-420 (2018); Stuart, T. et al. Cell 177, 1888-1902. e21 (2019)). Bioinformatics plots were generated using ggplot2 (v3.3.1)58, and heatmaps were generated with pheatmap (v1.0.12) (Kolde, R. & Vilo, J. F1000 Research vol. 4 574 (2015)). Data were scaled and normalized using the SCTransform function in Seurat (Hafemeister, C. & Satija, R. Genome Biol. 20, 296 (2019)). After principal component analysis (PCA), a uniform manifold approximation (UMAP) was created using 20 dimensions. Unsupervised clustering was performed using the FindClusters function at a resolution of 0.2, resulting in seven distinct clusters. Differentially expressed genes (cluster markers) were identified between clusters using the Wilcoxon rank sum test and a minimum upregulation of 0.25 log-fold using the FindAllMarkers function. The average overexpression of cell type signatures (EPI, TE, PE, non-reprogrammed (NR)) was calculated using the AddModuleScore function and the gene signatures published by Petropoulos, S. et al. Cell 165, 1012-1026 (2016) and Liu et al. (Nature 2020 Sep 16. doi:10.1038 / s41586-020-2734-6), respectively. Using canonical markers, the Petropoulos and Liu signatures as evidence, cell types were manually assigned to clusters. The remaining cell populations were classified as "intermediate" (IM) and enumerated (Rossant, J. & Tam, PPLCell Stem Cell vol.20 18-28 (2017); Harrison, et al. Science 356, (2017); Sozen, B. et al. Nat. Cell Biol.20,979-989(2018)).Finally, the cyclone function from the scran package (Scialdone, A. et al. Methods 85, 54-61 (2015)) was used to calculate cell cycle scores and assign cell phases based on the highest probability.
[0246] Integrated scRNA-seq analysis Previously published single-cell datasets from Petropoulos, S. et al. Cell 165, 1012-1026 (2016) (Petropoulos) and Blakeley, P. et al. Development 142, 3613 (2015) (Blakeley) were integrated with the iBlastoid data presented here. First, cells from the NR cluster were removed from the iBlastoid data as they were irrelevant for this integration. Petropoulos' total of 1,529 cells were filtered for blastocyst cells to remove pre-blastocyst cells, leaving 1,096 E5-E7 EPI, TE, and PE cells. Petropoulos' data and Blakeley's 30 cells were processed using SCTransform. After identifying integration genes using 4,000 anchor genes derived from the SCT assay (FindIntegrationAnchors and IntegrateData), both datasets were integrated into the iBlastoid data. This combined dataset contains 7,861 cells, 23,308 genes, and 4,000 integrated genes. Dimensionality was reduced using PCA and UMAP (20 dimensions), and clusters were identified using FindClusters (resolution 0.2). Cluster identities for five individual clusters were manually assigned using colocalization of cell identities from all three datasets and marker and signature expression as evidence. Using integrated gene expression values and Pearson correlation, transcriptome correlation was calculated with the average gene expression values of all cells a) with the same original cell identity (cluster ids of iBlastoid, EPI, TE, and PE for Blakeley; E5-7 EPI, TE, and PE for Petropoulos) or b) of the same cell type (aggregates of all EPI, TE, and PE cells, plus IM for iBlastoid).
[0247] In vitro adhesion assay iBlastoids were generated as described in Example 3 above. An in vitro attachment assay, often used as an embryo implantation model, was performed by adapting previously published protocols (Shahbazi, et al. Nat. Cell Biol. 18, 700-708 (2016); Deglincerti, A. et al. Nature 533, 251-254 (2016)). Briefly, the resulting iBlastoids were transferred to optical-grade tissue culture plates (Eppendorf) and cultured in IVC1 medium at 37°C in a 5% O2 and 5% CO2 incubator. On day 2 of the attachment assay, the culture medium was switched to IVC2 medium. iBlastoids were cultured in the attachment assay until day 4.5 and then harvested for analysis. Details of the culture medium used for this in vitro attachment assay are summarized in Example 2.
[0248] Statistics and Reproducibility For Figure 2a, we reanalyzed day 21 fibroblast reprogramming intermediate scRNA-seq data from a previous study (Liu et al. (Nature 2020 Sep 16. doi:10.1038 / s41586-020-2734-6)) for 4,761 cells using iBlastoid. For scRNA-seq data, a total of 6,858 cells from n = 2 biological replicates were included in all analyses used in this study. For the human blastocyst scRNA-seq dataset used in this study, a total of 1,096 cells from the Petropoulos dataset and 30 cells from the Blakeley dataset were included in the analysis. For the iBlastoid and human blastocyst integrated dataset, a total of 7,861 cells were included in the analysis. For Figure 1b, iBlastoids were generated from three different donor fibroblasts from two independent reprogramming experiments (n = 5 biological replicates), and a representative image is shown in this figure. For Figure 1c, immunostaining was performed on iBlastoids from three different donors from two independent reprogramming experiments (n = 5 biological replicates), and similar results were obtained; a representative image is shown in this figure. Representative images are shown. For Figures 1e-1h, data for human blastocysts are referenced in eight references (n = 8). Quantification of various iBlastoid parameters was performed on 18 independent iBlastoids obtained from three different donors (n = 18 biological replicates). For Figure 1i, cell number quantification was performed on 14 independent iBlastoids obtained from three different donors (n = 14 biological replicates). For Figures 1j-1l, immunostaining was performed on iBlastoids from three different donors in two independent reprogramming experiments (n = 5 biological replicates). Similar results were obtained; representative images are shown here. For Figure 1m, immunostaining was performed on iBlastoids from three different donors (n = 3 biological replicates). Similar results were obtained; representative images are shown here.For Figures 1n-1r, immunostaining was performed on iBlastoids from two different donors (n = 2 biological replicates), with similar results. Representative images are shown in this figure. Dense keratin 8 (KRT8) fibrous tissue with outer TE-like cells was also observed in the iBlastoids, consistent with what is typically observed in blastocysts (Figure 1s).
[0249] For Figure 7a, an in vitro adhesion assay was performed using iBlastoids derived from three different donor fibroblasts from two independent reprogramming experiments (n = 5 biological replicates); a representative image is shown here. For Figures 7b-c, immunostaining was performed on iBlastoids from two different donors (n = 2 biological replicates); similar results were obtained; a representative image is shown here. For Figure 7e, immunostaining was performed on iBlastoids from two different donors from two independent reprogramming experiments (n = 4 biological replicates); similar results were obtained; a representative image is shown here. For Figures 7f-g, immunostaining was performed on iBlastoids from two different donors (n = 2 biological replicates); similar results were obtained; a representative image is shown here. For Figure 7h, fold changes in CSH1 and ITGA1 expression were measured in technical replicates from n = 5 independent experiments. Data are presented as mean ± sem. For Figure 7i, hCG ELISA was performed on technical replicates in n = 4 independent experiments. Data are presented as mean ± sem. For Figure 2b, iBlastoids were generated from fibroblasts from three different donors in two independent reprogramming experiments (n = 5 biological replicates); a representative image is shown here. For Figure 2c, iBlastoid efficiency was quantified by counting 100 independent 3D structures obtained (n = 100 biological replicates). For Figure 2d, an experiment was performed with n = 3 biological replicates from three different donors; similar results were obtained; a representative image is shown here. For Figure 2e, immunostaining was performed on iBlastoids from three different donors in two independent reprogramming experiments (n = 5 biological replicates); similar results were obtained; a representative image is shown here. For Figures 2f-g, immunostaining was performed on iBlastoids from two different donors (n = 2 biological replicates), with similar results. Representative images are shown in this figure.For Figure 8b, fold changes in expression of TBXT, Eomes, and MIXL1 were measured in technical replicates from two independent donors (n = 6). Data are presented as mean ± SEM. For Figure 8c, immunostaining was performed on iBlastoids from three different donors (n = 5 biological replicates) from two independent reprogramming experiments, with similar results; representative images are shown here. For Figure 8d, immunostaining was performed on iBlastoids from three different donors (n = 3 biological replicates), with similar results; representative images are shown here. For Figures 8e–8f, immunostaining was performed on iBlastoids from two different donors (n = 2 biological replicates), with similar results; representative images are shown here.
[0250] Example 5 - iBlastoid Characterization Results To further confirm the identity and spatial localization of cells within iBlastoids, we performed co-immunostaining for the EPI marker NANOG and the TE marker CDX2. We then applied and analyzed confocal imaging to obtain three-dimensional (3D) representations of iBlastoids. The results show that NANOG-positive cells are exclusively localized in the ICM-like compartment, while CDX2-positive cells are found in the outer layer resembling the TE (Figure 1j).
[0251] Three-dimensional reconstruction and overlay of differential interference contrast (DIC) and fluorescent images confirmed the spatial localization of NANOG- and CDX2-positive cells and the presence of a blastocoel-like cavity formed in the iBlastoid constructs, resembling blastocysts (Shahbazi, M. et al. Nat. Cell Biol. 18, 700-708 (2016); Deglincerti, A. et al. Nature 533, 251-254 (2016); Xiang, L. et al. Nature 577, 537-542 (2020)) (Figure 1k, Figure 1l). Consistent with the origin of the iBlastoid constructs (i.e., derived from reprogrammed fibroblasts), no zona pellucida was observed. Importantly, we were able to confirm these results with iBlastoids generated from two additional fibroblast donors across multiple rounds of iBlastoid generation (Figure 2e).
[0252] To further characterize EPI and TE-like cells in iBlastoids, we tested the combination of two additional EPI markers (OCT4, also known as POU5F1 and SOX2) and a TE marker (GATA2) in iBlastoids. As described for human blastocysts (Fogarty, NME et al. Nature 550, 67-73 (2017); Boroviak, T. et al. Development 145, (2018)), outer TE-like cells were GATA2 positive, while significant colocalization of OCT4 and SOX2 was observed in the ICM-like compartment (Figure 1m). To assess the presence of PE-like cells in iBlastoids, we first performed immunostaining for the PE marker SOX17 in parallel with GATA2 (a TE marker) and NANOG (an EPI marker). We identified SOX17-positive cells surrounding NANOG-positive cells within the ICM-like compartment (Fig. 1n, Fig. 2f), which was similar to what has been reported for E6-7 blastocysts (Xiang, supra; Wamaitha, SE et al. Nat. Commun. 11, 764 (2020)).
[0253] To further validate this, we performed additional immunostaining using another PE marker, GATA6, in combination with CDX2 (a TE marker) and OCT4 (an EPI marker). We observed a "salt-and-pepper" pattern in the TE-like compartment, as indicated by the colocalization of GATA6 and CDX2 staining (Fig. 1o, Fig. 2g). Although initially puzzling, this pattern has previously been reported, where GATA6 was ubiquitously detected in E6-7 human blastocysts (Deglincerti, supra; Roode, M. et al. Human hypoblast formation is not dependent on FGF signaling. Dev. Biol. 361, 358-363 (2012); Kuijk, E. Wet et al. The roles of FGF and MAP kinase signaling in the segregation of the epiblast and hypoblast cell lineages in bovine and human embryos. Development 139, 871-882 (2012)). Importantly, upon further investigation, we observed GATA6-positive cells (with low or weak CDX2 staining) adjacent to OCT4-positive cells in the ICM-like compartment, suggesting the possible presence of GATA6-positive PE-like cells in iBlastoids (Figure 1o).
[0254] In human blastocysts, there are clear differences in cell morphology between TE and EPI lineage cells: TE cells display a "classical" elongated epithelial morphology, while EPI cells are smaller and more densely packed due to the constraints of the ICM (Kovacic, B., Vlaisavljevic, V., Reljic, M. & Cizek-Sajko, M. Reprod. Biomed. Online 8, 687-694 (2004)). To examine whether there are any differences in the cell morphology of EPI-like and TE-like cells in iBlastoids, we visualized the cellular organization of iBlastoids using the cell membrane marker F-actin (also known as phalloidin) (Figures 1p-r). The results show that the compact, NANOG-positive EPI-like cells had a more columnar appearance, while the TE-like cells surrounding the blastocoel cavity were flattened, highlighting the ability of this model to recapitulate the differences in cellular organization between EPI and TE cells (Figure 1q). Collectively, these results demonstrate that iBlastoids exhibit key morphological features of E6-7 human blastocysts and can also model key molecular and spatial aspects of EPI, TE, and PE cells.
[0255] Example 6 - Single-cell transcriptome profiling of iBlastoids To further characterize the transcriptional composition of cells in iBlastoids, we performed single-cell RNA sequencing (scRNA-seq) using iBlastoids generated from two donors (Figure 3a). After quality control and stringent filtering, 6,858 cells were retained for downstream analysis (3,249 cells from donor 1 and 3,609 cells from donor 2), and a total of 14,224 genes were detected (Figure 4a). Uniform manifold approximate projection (UMAP) analysis of this scRNA-seq data showed that cells were evenly distributed, with no clustering based on donor or cell cycle stage (Figure 4b, Figure 4c). While Sendai-KLF4 transcripts could be detected, there was only minimal Sendai-KOS and Sendai-MYC expression in the scRNA-seq data (Figure 4d), indicating that exogenous OCT4 and SOX2 were not expressed or expressed at very low levels.
[0256] To identify putative EPI, TE, and PE cell clusters in the UMAP, we examined the expression of EPI markers (NANOG and OCT4 / POU5F1), TE markers (CDX2 and GATA2), and PE markers (SOX17 and GATA6) in our scRNA-seq iBlastoid dataset. As shown in Figure 3b, OCT4- and NANOG-expressing cells occupy distinct regions within the UMAP. In this context, more cells express endogenous OCT4 than NANOG, a feature observed in human blastocysts (see Methods) (Figure 4e). While SOX17- and GATA6-expressing cells were also found in restricted regions on the UMAP, we observed more heterogeneous expression of CDX2 and GATA2, which is also observed in scRNA-seq datasets generated from E5-7 human blastocysts (Figure 3b, Figure 4e).
[0257] To further confirm the cell identity and presence of EPI, TE, and PE lineages in iBlastoids, we applied a scoring system based on a set of EPI-, TE-, and PE-specific gene signatures defined by Petropoulos et al. (2016) using scRNA-seq of E5-7 human blastocysts (Fig. 3c). Using these defined signatures, we resolved distinct EPI, TE, and PE cell populations in the UMAP of the iBlastoid dataset. Further examination of the EPI, TE, and PE signatures separated by E5, E6, and E7 in the iBlastoid and blastocyst scRNA-seq datasets shows only negligible differences (Fig. 5a-b). Collectively, these results confirm the presence of EPI-, TE-, and PE-like cells in iBlastoids.
[0258] Example 7 - iBlastoids are transcriptionally similar to blastocysts To further disentangle the identity of cells within iBlastoids, we performed unsupervised clustering analysis and identified seven cell clusters (Figure 3d). Based on EPI, TE, and PE gene signatures, these clusters were assigned as the EPI, TE, or PE clusters. The remaining three clusters did not have a clear identity a priori and appeared to have intermediate signatures (clusters IM1-3) (Figures 6a-6b, Figure 3d). These remaining clusters are examples of cells with mixed transcriptional signatures. Interestingly, cluster IM1 highly expressed CDX2 as well as exogenous KLF4 (Figures 3b, 4d), which may suggest that these cells are on their way to becoming TE-like cells. Similarly, mouse blastoids generated from EPSCs possess cell clusters with intermediate or undefined signatures, as revealed by scRNA-seq transcriptome profiling. We also observed cell clusters corresponding to non-reprogrammed, refractory fibroblasts (Fig. 4f, g), and these small fibroblast clusters were excluded from downstream analysis.
[0259] TE cells in human blastocysts are specified as polar TEs and mural TEs during embryonic development. Examination of polar TE and mural TE signatures as defined by Petropoulos et al. in iBlastoids revealed that iBlastoids contain two distinct TE cell populations, one expressing a higher polar TE-associated signature and the other expressing a mural TE signature (Figures 3j, 3k, and 3l). Immunostaining analysis of the polar marker CCR713 also suggested higher expression at the polar side of iBlastoids (Figures 3m and 3n).
[0260] To determine the degree to which iBlastoid cells resemble those in blastocysts generated after IVF, we integrated iBlastoid scRNA-seq with two additional scRNA-seq datasets obtained from human blastocysts previously reported by the Lanner and Niakan groups. The Lanner group's dataset was generated using Smart-seq2 on triturated cells, and a subset of E5-7 samples was enriched for ICM cells by immunosurgery. For the Niakan group's dataset, ICM and polar TE were isolated from blastocysts using laser biopsy micromanipulation, and cDNA was generated from isolated single cells and sequenced. UMAP analysis revealed high concordance between blastocyst and iBlastoid cells (Figures 3e, 3f, 6c, and 6d). Importantly, cells from the EPI-iBlastoid, TE-iBlastoid, and PE-iBlastoid clusters overlapped with their EPI, PE, and TE counterparts from blastocysts (Figure 3e). To further characterize these cell populations, we performed unsupervised clustering (Figures 3g and 3h), confirming that PE-, EPI-, and TE-like cells from iBlastoids shared the same cluster with PE, EPI, and TE cells from blastocysts. In this regard, we also observed that some blastocyst TE cells clustered with cells from the IM1-iBlastoid cluster (Figure 3e). Furthermore, correlation analysis of iBlastoid EPI, TE, and PE clusters with annotated EPI, TE, and PE cells from E5-7 blastocysts revealed a high correlation (approximately 0.9) between the iBlastoid clusters and their blastocyst counterparts (Figure 3i). We correlated iBlastoid cell clusters with EPI, TE, and PE cells from blastocysts at different developmental ages (E5, E6, and E7) in the Petropoulos dataset and observed a correlation between iBlastoid clusters and the EPI / TE / PE lineages at the E5-7 blastocyst stage (Figure 6e).Hierarchical clustering analysis suggests a better correlation between iBlastoid EPI clusters and early blastocyst EPIs (E5 and E6). Collectively, this data demonstrates that iBlastoid cells faithfully recapitulate the transcriptional makeup of these three cell lineages present in E5-6 human blastocysts.
[0261] Example 8 - iBlastoids can model in vitro implantation To assess whether iBlastoids can be used to model the morphological and molecular changes that occur during the peri- and early postimplantation windows of human embryo development in the absence of a uterus, we performed an in vitro attachment assay by modifying previously published human embryo attachment cultures using human blastocysts. While there is currently no precedent for working with a human blastoid model, all experiments were approved by our institutional human research ethics committee, following previously published recommendations and adhering to the international agreement that cultures human embryos until 14 days post-fertilization and / or the formation of the primitive streak (PS), whichever occurs first. Given that the "14-day rule" cannot be applied to iBlastoids given that the starting fibroblasts were derived from adult donors, we focused on culturing iBlastoids for the shortest possible time—in this case, a maximum of 5 additional days (corresponding to approximately E11)—and terminating the experiment before morphological evidence of PS, to remain well within international guidelines. To exclude molecular evidence of PS formation, we performed a 24-hour time-course qRT-PCR analysis of several key primitive streak markers during 5-day embryonic adherent culture and found no upregulation of TBXT, Eomes, or MIXL1 or any morphological changes indicative of gastrulation (Figure 8b). Thus, 5-day iBlastoid adherent culture did not result in the formation of the EPI compartment. Nevertheless, by strictly adhering to the above parameters, we performed all subsequent human iBlastoid adherent culture experiments for a total of 4.5 days after iBlastoid formation.
[0262] Using the adherent culture model, most iBlastoids (>90%) attached within 24 hours, increased in size, flattened, and progressed to outgrowth formation, similar to what has been reported for human blastocysts (Figure 7a). After attachment, the number of NANOG- and OCT4 / SOX2-positive cells increased, indicating expansion of iBlastoid EPIs, similar to what has been observed when using human blastocysts (Figures 8c and 8d). Furthermore, CDX2- and GATA2-positive cells also expanded upon attachment (Figures 8c and 8d), indicating TE outgrowths of attached iBlastoids. Similar results were obtained using iBlastoids generated from two additional donors (not shown). Next, we examined the distribution of PE-like cells after attachment. Although many of them still co-stained with TE markers (GATA2 or CDX2), we observed that some SOX17- and GATA6-positive cells were localized around NANOG- or OCT4-positive EPIs (Figures 7b, 7c, 8e, and 8f).
[0263] It has previously been reported that EPI cells of human blastocysts polarize upon in vitro attachment, forming a lumen known as the primitive amniotic cavity. F-actin, OCT4, and aPKC immunostaining demonstrated a central lumen (marked by F-actin and aPKC) within the EPI compartment of approximately 20–30% of attached iBlastoids, radially surrounded by organized OCT4-positive cells (Figure 7d). We observed EPI-like cell polarization and the development of a primitive amniotic cavity-like cavity on day 3 of attachment.
[0264] Next, we investigated possible cell fate transitions of the TE lineage upon attachment. Notably, we found intense filamentous keratin KRT7 (a pan-trophoblast marker) staining of TE cells in attached iBlastoids, in contrast to the limited, dark KRT7 staining in iBlastoids prior to attachment (Figure 7e). These results suggest a transition of the TE cell state toward the trophoblast lineage, as also reported when culturing human blastocysts. Importantly, we observed that cells surrounding the EPI-like compartment in attached iBlastoids possessed larger nuclear volumes compared to cells in the EPI, indicative of trophoblastic cells (Figure 7f). Notably, we found that some cells morphologically resembled syncytiotrophoblasts (ST) and extravillous trophoblasts (EVT), as evidenced by their respective multinucleated phenotypes and spindle-like morphologies around attached iBlastoids (Figure 7f).
[0265] To further verify the presence of ST- and EVT-like cells, we performed immunostaining using hCG as an ST marker and MMP2 as an EVT marker (Figure 7g). We detected strong and widespread staining for hCG, reflecting the early development of ST; whereas, MMP2 was detected in fewer cells, consistent with the delayed development of EVT during implantation (Figure 7g). In addition, qRT-PCR analysis revealed attachment-associated upregulation of the ST marker CSH1 and the EVT marker ITGA117, indicating that iBlastoid TE cells can differentiate into ST- and EVT-like states (Figure 7h, Figure 10).
[0266] Finally, we performed hCG ELISA on conditioned medium collected from attached iBlastoids and detected a 10-fold increase in hCG levels 4.5 days after attachment (Figure 7i). Collectively, these results demonstrate that iBlastoids can be used to model in vitro implantation similar to blastocysts, highlighting the fact that they are a valuable model system that allows feasible analysis of pre- and early post-implantation stages of human embryonic development.
[0267] Here, we present an in vitro human blastocyst model system. Unlike the approach used to generate mouse blastoids, we developed a strategy for generating human iBlastoids based on directly reprogramming fibroblasts into iBlastoids. Therefore, this approach eliminates the need to induce and expand the three stem cell types present in human blastocysts prior to aggregation. Because iBlastoids are generated from somatic cells rather than stem cells from embryonic sources, we anticipate this will facilitate widespread acceptance of iBlastoids as a model, similar to the acceptance of iPSCs in the past. As shown herein, iBlastoids can faithfully recapitulate an integrated model of human blastocyst development, including TE and EPI-like layers with cavity formation, as well as the spatial arrangement of cell types within the human blastocyst (Figure 1). Furthermore, iBlastoid cells are transcriptionally similar to cells in human blastocysts (Figures 3-6), and can be used to model in vitro some of the key functional properties of the human blastocyst during implantation (Figure 7).
[0268] Based on transcriptional analysis, EPI-like cells in iBlastoids correspond to E5 / E6 EPI cells from blastocysts, while PE- and TE-like cells correlate better with the E7 stage. This may reflect some cellular heterogeneity among iBlastoids, or raise the possibility that these three lineages are not fully synchronized in the iBlastoid model. While TE-, EPI-, and PE-like cells from iBlastoids did not express reprogramming factors, we found that a cluster of iBlastoid cells (the IM-1 and IM-2 clusters) still expressed the exogenous KLF4 gene. These cells also expressed CDX2 and GATA6, but did not exhibit a strong overall TE or PE signature, likely due to coexpression of exogenous KLF4. However, the IM-1 cluster showed good correlation (approximately 0.6) with E6-TE, and therefore, not surprisingly, some TE cells from blastocysts occupy the same UMAP space. These data demonstrate that iBlastoids represent an important model system—accessible, scalable, and tractable—with numerous applications in basic and translational research. For example, iBlastoids provide an in vitro platform for mimicking early cell fate transitions during embryonic development. Furthermore, because the coordinated interactions between TEs and PEs have largely been ignored, we anticipate that iBlastoids may challenge and refine our existing knowledge and understanding of human pluripotency by re-establishing in vitro the crucial embryonic-extraembryonic interface that controls so many critical events in normal early embryonic development. Given the ability to generate iBlastoids with specific gene loads, this will enable the study of early developmental disorders such as aneuploidy, hydatidiform mole, Cornelia de Lange syndrome, and therapeutic screening. iBlastoids may also serve as an excellent platform for developing genetic manipulation and gene editing techniques.In summary, iBlastoids offer new opportunities to model the pre-implantation blastocyst stage and peri-implantation stages of human embryonic development in vitro, and therefore hold tremendous potential for understanding infertility and early pregnancy loss.
[0269] Example 9 - Co-culture of iPSCs and iTSCs in a 3D culture system To facilitate observation of the aggregation between iPSCs and iTSCs, we first generated iPSC lines with a GFP reporter (iPSC-GFP) and iTSC lines with an mCherry reporter (iTSC-mCherry) by lentiviral transduction of GFP and mCherry empty vector constructs, respectively (Figures 9a and 9b). For co-culture experiments, dissociated cells were cultured in iBlastoid medium on 24-well AggreWell™ 400 plates under different conditions: (1) iPSCs and iTSCs were cultured at a ratio of 1:2.5 at 1.2 × 10 cells per well. 5 (2) 1.2 × 10 total cells per well for iPSCs only (Figure 9c); 5 (3) 1.2 × 10 total cells per well for iTSCs alone (Figure 9d); 5 The total cell count was 100 (Figure 9e). ROCKi was supplemented on the first day of co-culture to enhance cell survival, and the cells were cultured in the AggreWell system for 6 days. 3D structures obtained on day 6 of formation were harvested for downstream analysis (Figure 9c-9e).
[0270] Example 10 - Generation of reprogramming intermediates using different media To explore the potential for improving the ratio of EPI-, TE-, and PE-like cells at day 21 of reprogramming, we evaluated various signaling pathways / culture conditions known to regulate early embryonic and extraembryonic lineage cell fates. We explored reprogramming in various culture media, including those listed in Table 3a herein. Specifically, NACL medium has been reported to promote PE-like cell fates; PA medium promotes TE-like cell fates; and t2iLGo medium promotes preimplantation EPI-like cell fates. Based on immunofluorescence analysis of day 21 reprogrammed cells (Figure 11), NACL medium promoted expression of GATA6 (PE) and KLF17 (EPI); PA medium promoted upregulation of GATA3 (TE), GATA6 (PE), and KLF17 (EPI), while t2iLGo medium promoted upregulation of KLF17 (EPI). Of the conditions tested, PA medium gave rise to the greatest number of TE, PE and EPI-like cells at day 21 of reprogramming based on these three markers assessed.
[0271] Example 11 - Reprogramming of human fibroblasts by OKSMNL-mRNA transfection Reprogramming of human fibroblasts in this approach is mediated by OCT4, SOX2, KLF4, c-MYC, NANOG, and LIN28, collectively known as OKSMNL. For somatic cell reprogramming by the mRNA approach, experiments were performed according to the manufacturer's instructions for the StemRNA 3rd Generation Reprogramming Kit (StemGent, catalog number 00-0076) with modifications. To perform reprogramming, 1-2 x 10 cells were used per well of a 12-well plate. 4Human fibroblasts were seeded in fibroblast medium. 24 hours later (day 0), the cells were transfected with NM-RNA reprogramming transfection complexes containing OSKMNL NM-RNA, EKB NM-RNA, and NM-microRNA, prepared in Opti-MEM (Gibco) and RNAiMAX (Invitrogen) according to the manufacturer's instructions. After 18 hours, the medium was replaced with fresh fibroblast medium, and the next transfection was performed 6 hours later. This transfection process was repeated for an additional 3 days (for a 4x transfection regime) or 5 days (for a 6x transfection regime). Cells were cultured in fibroblast medium until day 21 of reprogramming and then harvested for further analysis. Further details of the medium used in these experiments are provided in Example 2.
[0272] On day 21, cells were immunostained to determine the expression of OCT4, GATA6, and CDX2 (Figures 12a and 12c), GATA2, NANOG, and SOX17 (Figures 12b and 12d) generated from 4xOKSMNL and 6xOKSMNL mRNA transfections.
[0273] These results demonstrate that reprogrammed intermediates can be obtained from human fibroblasts using alternative reprogramming methodologies and have gene expression profiles of markers OCT4, GATA6, CDX2, GATA2, NANOG, and SOX17 similar to those obtained as described in Example 3. These results indicate that reprogrammed intermediates generated using alternative methodologies also exhibit epiblast (EPI), trophectoderm (TE), and / or primitive endoderm (PE) transcriptional signatures. These results indicate that iBlastoids may be derived from reprogrammed intermediates obtained using alternative reprogramming methods, particularly those obtained by driving the expression of reprogramming transcription factors in different ways.
[0274] Example 12 - Reprogramming of human mesenchymal stem cells (hMSCs) by Sendai virus-mediated reprogramming hMSCs were reprogrammed using the CytoTune-iPS 2.0 Sendai Reprogramming Kit (ThermoFisher, lot no. 2170052) according to the manufacturer's instructions. Approximately 5–10 × 10 hMSCs were reprogrammed in MSC medium. 4 Cells were seeded at a density of 1000 x g / ml. Approximately 36 hours later, cells were transduced with Sendai virus in FM at the following multiplicities of infection (MOI): KOS MOI=5, c-MYC MOI=5, and KLF4 MOI=6. Medium changes were performed every other day starting on day 1 post-transduction and daily from day 8 onwards. On day 21 of reprogramming, reprogrammed cells were harvested for further analysis. Further details of the media used in these experiments are provided in Example 2.
[0275] On day 21, cells were immunostained to determine the expression of OCT4, GATA6, and CDX2 (FIG. 13a) or GATA2, NANOG, and SOX17 (FIG. 13b).
[0276] These results demonstrate that reprogrammed intermediates can be obtained from another somatic cell, in this case hMSCs, and have gene expression profiles of markers PCT4, GATA6, CDX2, GATA2, NANOG, and SOX17 similar to those obtained as described in Example 3. These results indicate that reprogrammed intermediates generated from another somatic cell also exhibit epiblast (EPI), trophectoderm (TE), and / or primitive endoderm (PE) transcriptional signatures. These results also indicate that iBlastoids may potentially be derived from reprogrammed intermediates obtained by different reprogramming methods, particularly different somatic cell types.
[0277] Example 13 - Reprogramming of human peripheral blood mononuclear cells (hPBMCs) by Sendai virus-mediated reprogramming. hPBMCs were reprogrammed using the CytoTune-iPS 2.0 Sendai Reprogramming Kit (ThermoFisher, Lot No. 2170052) according to the manufacturer's instructions. To perform this reprogramming, 2.5–5 × 10 5 hPBMCs were counted and transferred to a 12 mL round-bottom tube. Reprogramming mixtures were prepared by adding a calculated volume of Sendai virus to 1 mL of PBMC medium at the following multiplicities of infection (MOI): KOS MOI=5, c-MYC MOI=5, and KLF4 MOI=6.
[0278] After transferring the reprogramming mixture to the round-bottom tube containing hPBMCs, the cells were centrifuged at 1000 × g for 30 minutes at room temperature. An additional 1 mL of PBMC medium was added to the centrifuged cells, and the contents were resuspended and transferred to a single well of a 12-well plate and incubated overnight at 37°C (day 0). The following day (day 1), the medium was replaced with fresh PBMC medium. On day 3, cells were plated at a 1:3 ratio in fresh PBMC medium on Matrigel-coated plates. On days 4 and 6, medium changes were performed by removing half of the spent medium and replacing it with fresh StemPro34 medium (cytokine-free PBMC medium). On day 8 of reprogramming, cells were switched to either StemPro34 medium or StemPro34 medium supplemented with 10% FBS, with medium changes occurring every other day from this point onward. Cells were harvested on days 18 and 21 for further analysis. Further details on the medium used in these experiments are provided in Example 2.
[0279] On days 18 and 21, cells were immunostained to determine the expression of OCT4, GATA6, and CDX2 (FIGS. 14a to 14c) or GATA2, NANOG, and SOX17 (FIGS. 14d to 14f).
[0280] These results demonstrate that reprogrammed intermediates can be obtained from other somatic cells, in this case human peripheral blood mononuclear cells, and have gene expression profiles of markers OCT4, GATA6, CDX2, GATA2, NANOG, and SOX17 similar to those obtained as described in Example 3. These results indicate that reprogrammed intermediates generated from other somatic cells also exhibit epiblast (EPI), trophectoderm (TE), and / or primitive endoderm (PE) transcriptional signatures. These results also indicate that iBlastoids can be derived from reprogrammed intermediates obtained by different reprogramming methods, particularly different somatic cell types.
[0281] It will be understood that the invention disclosed and defined herein extends to any and all alternative combinations of two or more of the individual features mentioned or apparent from the specification or drawings, all of which different combinations constitute various alternative aspects of the invention.
Claims
1. 1. A method for producing a multi-layered cell structure or a blastocyst-like structure, comprising: a) increasing the protein expression or amount of one or more factors in a population of somatic cells, said factors for reprogramming said somatic cells towards a dedifferentiated or pluripotent state; b) culturing said cells for a time and under conditions sufficient to allow said reprogramming of said cells towards a dedifferentiated or pluripotent state; c) contacting the cells with a culture medium comprising an activator of WNT pathway signaling (preferably a GSK-3 inhibitor), at least one TGF-β inhibitor, an HDAC inhibitor, EGF, and BMP4 under conditions that allow aggregation; d) culturing said cells in said culture medium for a sufficient time and under conditions to allow aggregation and / or to allow said cells to exhibit at least one characteristic of a blastocyst-like structure as described herein. in turn, thereby producing a multi-layered cell structure or a blastocyst-like structure.
2. (a) the culture medium of step c) comprises at least two TGF-β inhibitors; and / or (b) the culture medium of step c) further comprises a Rho kinase (ROCK) inhibitor; Optionally, the cells are contacted with the culture medium containing a ROCK inhibitor for about 24 hours, and then contacted with the culture medium without the ROCK inhibitor. The method of claim 1.
3. The factor for reprogramming a somatic cell towards a dedifferentiated or pluripotent state is a transcription factor, and optionally (a) the transcription factors comprise one or more of OCT4, SOX2, KLF4 and MYC or variants thereof, preferably the transcription factors comprise all four of the factors OCT4, SOX2, KLF4 and MYC (OSKM) or variants thereof; (b) the transcription factor comprises all four of the factors SOX2, KLF4 and OCT4 (SKO) or mutants thereof; (c) the transcription factors include one or more of OCT4, SOX2, KLF4 and GLIS1 or variants thereof, optionally the transcription factors include all four of the factors OCT4, SOX2, KLF4 and GLIS1 (OSKG); (d) the transcription factors include one or more of OCT4, SOX2, NANOG and LIN28 (OSNL), optionally the transcription factors include all four of the factors OCT4, SOX2, NANOG and LIN28 (OSNL); or (e) the transcription factors include all six of the factors OCT4, SOX2, KLF4, c-MYC, NANOG and LIN28 (OKSMNL); The method according to claim 1 or 2.
4. The protein expression or amount of a factor for reprogramming a somatic cell towards a pluripotent state, (a) increasing expression of said factor by contacting said somatic cells with an agent that increases expression of said factor, optionally wherein said agent is selected from the group consisting of nucleotide sequences, proteins, aptamers and small molecules, ribosomes, RNAi agents and peptide nucleic acids (PNAs) and analogs or variants thereof; (b) by introducing into said cell at least one nucleic acid comprising a nucleotide sequence encoding at least one factor for reprogramming said somatic cell towards a pluripotent state, or encoding a functional fragment thereof, optionally said nucleic acid being RNA, preferably mRNA, or said nucleic acid sequence being introduced into the cell by a plasmid, a viral vector or a non-viral vector; or (c) multiplying the somatic cells by transducing or transfecting one or more vectors encoding the transcription factors, optionally wherein the vectors are viral vectors, including integrative or non-integrative viral vectors; 4. The method according to any one of claims 1 to 3.
5. (a) the somatic cell is a reprogramming intermediate; (b) the cells are cultured under the conditions of step b) for at least 1 day, or for at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 days, or for at least 22, at least 24, at least 28 days or more; and / or (c) the markers characteristic of the somatic cells are reduced before the step of culturing the reprogrammed somatic cells under conditions allowing aggregation to obtain a multi-layered cell structure or a blastocyst-like structure or before the step of contacting the cells with a culture medium in step c).
5. The method according to any one of claims 1 to 4.
6. culturing said cells towards a dedifferentiated or pluripotent state in a medium that induces upregulation of epiblast (EPI), trophectoderm (TE) and primitive endoderm (PE) lineage transcriptional signatures; Preferably, the medium is a fibroblast medium, such as a fibroblast medium as defined herein, including those in Table 3a or Table 3b.
6. The method according to any one of claims 1 to 5.
7. 7. The method of any one of claims 1 to 6, wherein the cells are cultured in the culture medium of step c) for at least about 1 day, at least about 2 days, at least about 3 days, at least about 4 days, at least about 5 days, at least about 6 days, at least about 8 days, at least about 10 days, at least about 15 days, at least about 20 days, at least about 24 days or more.
8. The conditions allowing aggregation include culturing in any culture plate, culture vessel or culture system that allows three-dimensional aggregation of cells; Optionally, the cells are cultured at a concentration of 0.5 to 2×10 per well in the culture plate, culture vessel or culture system. 5 Or about 0.5 to 2 × 10 5 Cells, 0.6-2 x 10 per well 5 Or about 0.6 to 2 × 10 5 Cells, 0.8-2 x 10 per well 5 Or about 0.8 to 2 × 10 5 Cells, 1-2 x 10 per well 5 Or about 1 to 2 × 10 5 Cells, 0.6 x 10 per well 5 Or about 0.6 x 10 5 Cells, 0.8 x 10 per well 5 or about 0.8 x 10 cells, 1 x 10 per well 5 Or about 1×10 5 Cells, 1.2 x 10 per well 5 Or about 1.2 × 10 5 Cells, 1.4 x 10 per well 5 Or about 1.4 × 10 5 Cells, 1.6 x 10 per well 5 Or about 1.6 x 10 5 Cells, 1.8 x 10 per well 5 Or about 1.8 x 10 5 Cells or 2 x 10 per well 5 Or about 2 x 10 5 Cells are seeded at a density of 8. The method according to any one of claims 1 to 7.
9. The multi-layered cell structure or blastocyst-like structure comprises an inner cell layer and an outer cell layer, the inner cell layer comprising cells exhibiting one or more characteristics of cells of the epiblast (EPI) and / or primitive endoderm (PE) lineage, and the outer cell layer comprising cells exhibiting one or more characteristics of cells of the trophectoderm (TE), Optionally, (a) the inner cell layer further comprises a cell mass exhibiting one or more characteristics of PE, and preferably the cells exhibiting one or more characteristics of PE are surrounding or primarily surrounding the cells exhibiting one or more characteristics of epiblast cells. (b) the characteristic of EPI cells is the presence of any one or more of the markers NANOG, OCT4 (also known as POU5F1) or SOX2, and / or a columnar appearance morphology; (c) the characteristic of TE cells is the presence of one or more of the markers CDX2 and GATA2 and / or a flat or elongated epithelial morphology; and / or (d) the characteristic of PE cells is the presence of the markers SOX17 or GATA6; 9. The method according to any one of claims 1 to 8.
10. (a) said multi-layered cell structure or blastocyst-like structure exhibits the main morphological characteristics of an E5-7, preferably E6-7, human blastocyst; (b) said multi-layered cell structure or blastocyst-like structure comprises cells exhibiting one or more characteristics of epiblast, primitive endoderm and trophectoderm cells, said cells adopting the same or similar relative spatial arrangement as epiblast, primitive endoderm and trophectoderm cells, respectively, in an E5-7, preferably E6-7, human blastocyst; and / or (c) the multi-layered cell structure or blastocyst-like structure comprises an acellular cavity or a blastocoel-like cavity; 10. The method according to any one of claims 1 to 9.
11. 1. A method for producing a multi-layered cell structure or a blastocyst-like structure, the method comprising: Culturing iPSC and iTSC cells under conditions that allow aggregation and aggregation of said cells to obtain multi-layered cell structures, thereby producing multi-layered cell or blastocyst-like structures: Optionally, (a) the iPSCs and iTSCs are obtained from human cells, preferably by reprogramming human somatic cells; (b) the conditions allowing for the aggregation and aggregation of the cells include co-culturing the iPSCs and iTSCs in any culture vessel that promotes self-organization and aggregation of the cells; and / or (c) the cells are cultured in a culture medium that is iBlastoid medium as shown in Table 3a herein (i.e., a culture medium that comprises an activator of WNT pathway signaling (preferably a glycogen synthase kinase 3 (GSK-3) inhibitor), at least one transforming growth factor beta (TGF-β) inhibitor, a histone deacetylase (HDAC) inhibitor, epidermal growth factor (EGF), and bone morphogenetic protein 4 (BMP4). method.
12. 1. An in vitro derived or created multi-layered cell structure or blastocyst-like structure, said multi-layered cell structure or blastocyst-like structure comprising an inner cell layer and an outer cell layer, the inner cell layer comprises cells exhibiting one or more characteristics of cells of human epiblast (EPI) and / or human primitive endoderm (PE) lineages, and the outer cell layer comprises cells exhibiting one or more characteristics of cells of human trophectoderm (TE); Preferably, the multi-layered cell structure or blastocyst-like structure does not have a zona pellucida, More preferably, the inner cell layer further comprises a cell mass exhibiting one or more characteristics of PE, e.g., the cells exhibiting one or more characteristics of PE are surrounding or primarily surrounding the cells exhibiting one or more characteristics of epiblast cells. Multi-layered cell structures or blastocyst-like structures.
13. 12. A multi-layered cell structure or a blastocyst-like structure, said structure being obtained or obtainable by a method according to any one of claims 1 to 11.
14. 1. A culture medium for promoting cells, preferably reprogrammed intermediate cells, to exhibit at least one characteristic of a blastocyst-like structure, comprising: The culture medium comprises: - activators of WNT pathway signaling (preferably GSK-3 inhibitors); at least one, preferably two, TGF-β inhibitors, - HDAC inhibitors, - EGF, and - BMP4 Contains; Optionally, (a) the culture medium comprises: - ITS-X; - L-glutamine; N-acetyl-L-cysteine; - β-estradiol; - Progesterone; - 2-mercaptoethanol; - L-ascorbic acid; - transferrin (e.g. human), - insulin (e.g. human), - N2 supplement; and - B27 supplement Further comprising: (b) the TGF-β pathway inhibitor is selected from SB431542 and A83-01, the histone deacetylase (HDAC) 1 inhibitor is VPA (valproic acid), and the GSK-3 inhibitor is CHIR99021; and / or (c) the culture medium further comprises a ROCK inhibitor, preferably, the ROCK inhibitor is Y-27632, more preferably, the ROCK inhibitor is at a concentration of 10 μM or about 10 μM; Culture medium.
15. A kit for producing a multi-layered cell structure or a blastocyst-like structure, comprising somatic cells, reprogramming factors and a culture medium according to claim 14, and optionally instructions for reprogramming somatic cells into a multi-layered cell structure or a blastocyst-like structure according to the method disclosed herein. Optionally, a kit for use in the method according to any one of claims 1 to 11.
16. A method for producing a multi-layered cell structure or a blastocyst-like structure, comprising the steps of: a) increasing the protein expression or amount of one or more factors in a population of somatic cells, said factors for reprogramming said somatic cells towards a dedifferentiated or pluripotent state; b) culturing said cells for a time and under conditions sufficient to allow said reprogramming of said cells towards a dedifferentiated or pluripotent state; c) contacting the cells with a culture medium comprising an activator of WNT pathway signaling (preferably a glycogen synthase kinase 3 (GSK-3) inhibitor), at least one transforming growth factor beta (TGF-β) inhibitor, a histone deacetylase (HDAC) inhibitor, epidermal growth factor (EGF) and bone morphogenetic protein 4 (BMP4) under conditions allowing aggregation; d) culturing said cells in said culture medium for a sufficient time and under conditions to allow aggregation and / or to allow said cells to exhibit at least one characteristic of a blastocyst-like structure as described herein. A method comprising, in order:
17. The method of claim 16, wherein the culture medium of step c) further comprises a Rho kinase (ROCK) inhibitor.
18. 17. The method of claim 16, wherein the protein expression or amount of said factor for reprogramming a somatic cell towards a pluripotent state is increased by introducing into said cell at least one nucleic acid comprising a nucleotide sequence encoding at least one factor for reprogramming a somatic cell towards a pluripotent state or a functional fragment thereof.
19. 17. The method of claim 16, wherein the cells are cultured under the conditions of step b) for at least 1 day, or at least 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, or at least 22 days, at least 24 days, at least 28 days or more.
20. 17. The method of claim 16, wherein the conditions allowing aggregation include culturing in any culture plate, culture vessel or culture system that allows three-dimensional aggregation of the cells.
21. The method of claim 11, wherein the cells are cultured in any culture medium for promoting the cells to assume at least one characteristic of a blastocyst-like structure, the culture medium comprising an activator of WNT pathway signaling, preferably a glycogen synthase kinase 3 (GSK-3) inhibitor, at least one transforming growth factor beta (TGF-β) inhibitor, and a histone deacetylase (HDAC) inhibitor.
22. 12. The method of claim 11, wherein the culture medium comprises a GSK-3 inhibitor which is CHIR99021, at least one TGF-β inhibitor selected from SB431542 and A83-01, an HDAC inhibitor in the form of valproic acid, EGF and BMP4.
23. The method of claim 11 , wherein the culture medium further comprises a ROCK inhibitor.
24. 24. The method of claim 23, wherein the culture medium further comprises a ROCK inhibitor that is Y-27632.
25. 2. The method of claim 1, wherein the multi-layered cell structure or blastocyst-like structure comprises an inner cell layer, said inner cell layer further comprising a cell mass exhibiting one or more characteristics of PE, said cells exhibiting one or more characteristics of PE being surrounding or primarily surrounding cells exhibiting one or more characteristics of epiblast cells.
26. The method of claim 11 , wherein the iPSCs and iTSCs are obtained by reprogramming of human somatic cells.
